

Schizophrenia, "œjust the facts"œ. Clinical features a

Schizophrenia Research

110, 1-23

DOI: 10.1016/j.schres.2009.03.005

Citation Report

#	ARTICLE	IF	CITATIONS
1	Neurobiology of schizo-obsessive disorder. , 0, , 181-193.		0
2	Antipsychotic drug actions on gene modulation and signaling mechanisms. , 2009, 124, 74-85.		75
3	Newer conceptualizations of schizophrenia demand a name change. Schizophrenia Research, 2009, 115, 374.	1.1	3
4	Treatment of early-onset schizophrenia. Current Opinion in Psychiatry, 2010, 23, 304-310.	3.1	39
6	Epigenetics and Biomarkers in the Staging of Neuropsychiatric Disorders. Neurotoxicity Research, 2010, 18, 347-366.	1.3	22
7	New animal models of progressive neurodegeneration: tools for identifying targets in predictive diagnostics and presymptomatic treatment. EPMA Journal, 2010, 1, 217-227.	3.3	9
8	Metabotropic glutamate mGlu1 receptor stimulation and blockade: Therapeutic opportunities in psychiatric illness. European Journal of Pharmacology, 2010, 639, 2-16.	1.7	53
9	Research in people with psychosis risk syndrome: a review of the current evidence and future directions. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2010, 51, 390-431.	3.1	167
10	What is Bizarre in Bizarre Delusions? A Critical Review. Schizophrenia Bulletin, 2010, 36, 667-679.	2.3	110
11	Schizophrenia Psychopathology in a Kuwaiti Arab Sample. Psychopathology, 2010, 43, 345-356.	1.1	15
12	Bases Clínicas para un Nuevo Modelo de Atención a las Psicosis. Clinica Y Salud, 2010, 21, 299-318.	0.3	1
13	Time to "Get Real": Preliminary Insights into the Long-Term Management of Schizophrenia. Australasian Psychiatry, 2010, 18, 115-119.	0.4	3
14	Mutant Mouse Models: Genotype-Phenotype Relationships to Negative Symptoms in Schizophrenia. Schizophrenia Bulletin, 2010, 36, 271-288.	2.3	66
15	Pharmacogenetics of Schizophrenia: Bringing "Order to Chaos" in the Psychopharmacology of Schizophrenia?. Advances in Biological Psychiatry, 2010, , 46-57.	0.2	1
18	DSM, ICD, and psychiatric nosology: How do cultural and national differences factor in?. Asian Journal of Psychiatry, 2010, 3, 1-2.	0.9	1
19	Schizophrenia, "Just the Facts". Treatment and prevention Past, present, and future. Schizophrenia Research, 2010, 122, 1-23.	1.1	323
20	The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. Schizophrenia Research, 2010, 123, 199-207.	1.1	117
21	Interaction of hippocampal volume and N-acetylaspartate concentration deficits in schizophrenia: A combined MRI and 1H-MRS study. NeuroImage, 2010, 53, 51-57.	2.1	34

#	ARTICLE	IF	CITATIONS
22	Positive syndrome of schizophrenia and epilepsy. <i>Medical Hypotheses</i> , 2010, 74, 294-296.	0.8	6
23	Structural dynamics of dendritic spines in memory and cognition. <i>Trends in Neurosciences</i> , 2010, 33, 121-129.	4.2	707
24	Comparative genomics of autism and schizophrenia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 1736-1741.	3.3	271
25	Catatonia in the DSM--Shall We Move or Not?. <i>Schizophrenia Bulletin</i> , 2010, 36, 205-207.	2.3	62
26	Schizophrenia susceptibility gene <i>dysbindin</i> regulates glutamatergic and dopaminergic functions via distinctive mechanisms in <i>Drosophila</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18831-18836.	3.3	49
28	Practicing evidence-based psychiatry- 2. Interpreting integrative literature: Systematic reviews and meta-analyses. <i>Asian Journal of Psychiatry</i> , 2011, 4, 80-85.	0.9	4
29	Race/ethnicity and outcomes in psychosis. <i>Asian Journal of Psychiatry</i> , 2011, 4, 233.	0.9	0
30	Practicing evidence-based psychiatry. 3. Interpreting treatment guidelines. <i>Asian Journal of Psychiatry</i> , 2011, 4, 304-308.	0.9	3
31	Alexithymia and Personality Disorder Functioning Styles in Paranoid Schizophrenia. <i>Psychopathology</i> , 2011, 44, 371-378.	1.1	17
33	Altered social interaction in adult rats following neonatal treatment with domoic acid. <i>Physiology and Behavior</i> , 2011, 102, 291-295.	1.0	23
34	Early and broadly defined psychosis risk mental states. <i>Schizophrenia Research</i> , 2011, 126, 1-10.	1.1	105
35	Deficit and nondeficit schizophrenia: Boundaries in question. <i>Schizophrenia Research</i> , 2011, 130, 289-290.	1.1	5
36	Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: From the elephant to the mouse. <i>Schizophrenia Research</i> , 2011, 127, 3-13.	1.1	186
37	Moving on in Schizophrenia Research to the next decade. <i>Schizophrenia Research</i> , 2011, 127, 14-15.	1.1	9
38	Insight controlled for cognition in deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , 2011, 128, 124-126.	1.1	17
40	"Just the facts" of schizophrenia in the context of human evolution: Commentary on Keshavan et al. (2011). <i>Schizophrenia Research</i> , 2011, 129, 205-207.	1.1	1
41	What Kraepelin might say about schizophrenia: Just the facts. <i>Schizophrenia Research</i> , 2011, 128, 1-2.	1.1	5
42	The facts of schizophrenia: A personal commentary. <i>Schizophrenia Research</i> , 2011, 128, 3-4.	1.1	13

#	ARTICLE	IF	CITATIONS
43	â€œJust the factsâ€ Meandering in schizophrenia's many forests. <i>Schizophrenia Research</i> , 2011, 128, 5-6.	1.1	8
44	Antipsychotics, mortality and schizophrenia: What are the facts?. <i>Schizophrenia Research</i> , 2011, 133, 262-263.	1.1	2
45	Antipsychotic medication and mortality: A clarification. <i>Schizophrenia Research</i> , 2011, 133, 261.	1.1	0
46	Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 2011-2035.	2.5	235
47	Pharmacotherapy for treatment-refractory schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 411-434.	0.9	23
48	Management of Schizophrenia in Late Life with Antipsychotic Medications. <i>Drugs and Aging</i> , 2011, 28, 961-980.	1.3	26
49	If waking and dreaming consciousness became de-differentiated, would schizophrenia result?. <i>Consciousness and Cognition</i> , 2011, 20, 1059-1083.	0.8	30
50	Nocturnal hyperactivity, increased social novelty preference and delayed extinction of fear responses in post-weaning socially isolated mice. <i>Brain Research Bulletin</i> , 2011, 85, 354-362.	1.4	49
51	The role of recollection in source memory: An examination of schizophrenia patients and their first-degree relatives. <i>Brain and Cognition</i> , 2011, 75, 147-153.	0.8	4
52	Anti-inflammatory signaling in schizophrenia. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1507-1518.	2.0	62
53	Cholinergic systems mediate action from movement to higher consciousness. <i>Behavioural Brain Research</i> , 2011, 221, 488-498.	1.2	134
54	Minor physical anomalies: potentially informative vestiges of fetal developmental disruptions in schizophrenia. <i>International Journal of Developmental Neuroscience</i> , 2011, 29, 245-250.	0.7	25
55	Isolation rearing-induced deficits in sensorimotor gating and social interaction in rats are related to cortico-striatal oxidative stress, and reversed by sub-chronic clozapine administration. <i>European Neuropsychopharmacology</i> , 2011, 21, 471-483.	0.3	97
56	Cognitive and Socio-Emotional Deficits in Platelet-Derived Growth Factor Receptor- β^2 Gene Knockout Mice. <i>PLoS ONE</i> , 2011, 6, e18004.	1.1	50
57	Lurasidone: The Most Recent Addition to Our Antipsychotic Armamentarium. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2011, 46, 41-47.	0.1	3
59	Targeting Catechol-O-Methyl Transferase (COMT) Inhibitors for Schizophrenia: An Approach to Target Validation and Rational Drug Design. <i>Letters in Drug Design and Discovery</i> , 2011, 8, 246-252.	0.4	2
60	Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment. <i>Epidemiology and Psychiatric Sciences</i> , 2011, 20, 317-327.	1.8	60
61	Schizophrenia-relevant behaviors in a genetic mouse model of constitutive Nurr1 deficiency. <i>Genes, Brain and Behavior</i> , 2011, 10, 589-603.	1.1	38

#	ARTICLE	IF	CITATIONS
62	Violence among persons diagnosed with schizophrenia: How pharmacists can help. <i>Research in Social and Administrative Pharmacy</i> , 2011, 7, 421-429.	1.5	2
63	Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. , 2011, 132, 96-110.		217
64	Resting state cerebral blood flow and objective motor activity reveal basal ganglia dysfunction in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2011, 192, 117-124.	0.9	102
65	Schizophrenia and Autism: Both Shared and Disorder-Specific Pathogenesis Via Perinatal Inflammation?. <i>Pediatric Research</i> , 2011, 69, 26R-33R.	1.1	305
66	Association of the Met-196-Arg Variation of Human Tumor Necrosis Factor Receptor 2 (TNFR2) with Paranoid Schizophrenia. <i>Journal of Molecular Neuroscience</i> , 2011, 43, 358-363.	1.1	12
67	Susceptibility Genes for Schizophrenia: Mutant Models, Endophenotypes and Psychobiology. <i>Current Topics in Behavioral Neurosciences</i> , 2011, 12, 209-250.	0.8	5
68	Should Overeating and Obesity be Classified as an Addictive Disorder in DSM-5?. <i>Current Pharmaceutical Design</i> , 2011, 17, 1128-1131.	0.9	29
69	Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial. <i>Therapeutic Advances in Psychopharmacology</i> , 2011, 1, 111-124.	1.2	22
70	Unmet treatment needs in schizophrenia patients: is aripiprazole a potential therapeutic option?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 989-1006.	1.4	6
71	New visual information processing abnormality biomarkers for the diagnosis of schizophrenia. <i>Expert Opinion on Medical Diagnostics</i> , 2011, 5, 357-368.	1.6	14
72	Can I trust you? Negative affective priming influences social judgments in schizophrenia.. <i>Journal of Abnormal Psychology</i> , 2011, 120, 98-107.	2.0	59
73	DSM-5 Status of Psychotic Disorders: 1 Year Prepublication. <i>Schizophrenia Bulletin</i> , 2012, 38, 369-370.	2.3	42
74	Psychopharmacology of schizophrenia: The future looks bleak. <i>Mens Sana Monographs</i> , 2012, 10, 4.	0.2	6
75	Long-Range Regulatory Polymorphisms Affecting a GABA Receptor Constitute a Quantitative Trait Locus (QTL) for Social Behavior in <i>Caenorhabditis elegans</i> . <i>PLoS Genetics</i> , 2012, 8, e1003157.	1.5	52
76	Attenuated psychosis and the schizophrenia prodrome: current status of risk identification and psychosis prevention. <i>Neuropsychiatry</i> , 2012, 2, 345-353.	0.4	48
77	All-Cause Mortality and Medication Risk Factors in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 31-35.	0.7	27
78	Microduplications disrupting the MYT1L gene (2p25.3) are associated with schizophrenia. <i>Psychiatric Genetics</i> , 2012, 22, 206-209.	0.6	42
80	Olfaction and Cognition in Schizophrenia: Sex Matters. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2012, 24, 165-175.	0.9	20

#	ARTICLE	IF	CITATIONS
81	Crosstalk within GPCR Heteromers in Schizophrenia and Parkinsons Disease: Physical or Just Functional?. <i>Current Medicinal Chemistry</i> , 2012, 19, 1119-1134.	1.2	10
82	Pseudo-ADHD in a Case of First-Episode Schizophrenia: Diagnostic and Treatment Challenges. <i>Harvard Review of Psychiatry</i> , 2012, 20, 309-317.	0.9	1
83	Motor Symptoms and Schizophrenia. <i>Neuropsychobiology</i> , 2012, 66, 77-92.	0.9	278
84	Interventions for the metabolic syndrome in schizophrenia: a review. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2012, 3, 141-162.	1.4	47
85	Antipsychotic agents: efficacy and safety in schizophrenia. <i>Drug, Healthcare and Patient Safety</i> , 2012, 4, 173.	1.0	18
86	Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. <i>Schizophrenia Research and Treatment</i> , 2012, 2012, 1-12.	0.7	67
87	Poor school performance in offspring of patients with schizophrenia: what are the mechanisms?. <i>Psychological Medicine</i> , 2012, 42, 111-123.	2.7	24
88	Catatonic Schizophrenia: A Cohort Prospective Study. <i>Schizophrenia Bulletin</i> , 2012, 38, 331-337.	2.3	29
89	Nicotine dependence and illness severity in schizophrenia. <i>British Journal of Psychiatry</i> , 2012, 201, 306-312.	1.7	78
90	Disordered Corticolimbic Interactions During Affective Processing in Children and Adolescents at Risk for Schizophrenia Revealed by Functional Magnetic Resonance Imaging and Dynamic Causal Modeling. <i>Archives of General Psychiatry</i> , 2012, 69, 231.	13.8	63
91	More Than One Century of Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2012, 200, 1054-1057.	0.5	26
92	Current Progress in the Genetic Research of Schizophrenia: Relevance for Drug Discovery?. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1614-1621.	0.9	4
93	Parsing the components of the psychomotor syndrome in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2012, 126, 256-265.	2.2	79
94	Behavioral Animal Models of Antipsychotic Drug Actions. <i>Handbook of Experimental Pharmacology</i> , 2012, , 361-406.	0.9	29
97	S.02.03 Did we need such a long way to come back to Bleuler? The group of schizophrenias. <i>European Neuropsychopharmacology</i> , 2012, 22, S114.	0.3	0
99	Clozapine resistance: Augmentation strategies. <i>European Neuropsychopharmacology</i> , 2012, 22, 165-182.	0.3	121
100	Heterogeneity and symptom structure of schizophrenia. <i>Psychiatry Research</i> , 2012, 198, 386-394.	1.7	64
101	Schizotypal traits and neurocognitive functioning among nonclinical young adults. <i>Psychiatry Research</i> , 2012, 200, 635-640.	1.7	14

#	ARTICLE	IF	CITATIONS
102	Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 153-160.	1.3	11
103	To poly(I:C) or not to poly(I:C): Advancing preclinical schizophrenia research through the use of prenatal immune activation models. <i>Neuropharmacology</i> , 2012, 62, 1308-1321.	2.0	213
104	Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications. <i>Comprehensive Psychiatry</i> , 2012, 53, 480-483.	1.5	101
105	Immune system gene dysregulation in autism and schizophrenia. <i>Developmental Neurobiology</i> , 2012, 72, 1277-1287.	1.5	96
106	Association of CTXN3-SLC12A2 polymorphisms and schizophrenia in a Thai population. <i>Behavioral and Brain Functions</i> , 2012, 8, 27.	1.4	7
107	Association testing of copy number variants in schizophrenia and autism spectrum disorders. <i>Journal of Neurodevelopmental Disorders</i> , 2012, 4, 15.	1.5	63
108	The Nosology of Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2012, 35, 557-569.	0.7	61
109	Schizophrenia and the immune system: Pathophysiology, prevention, and treatment. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 757-766.	0.5	39
111	Aripiprazole. <i>CNS Drugs</i> , 2012, 26, 155-183.	2.7	58
112	Current Antipsychotics. <i>Handbook of Experimental Pharmacology</i> , 2012, , .	0.9	6
113	Disability and schizophrenia: a systematic review of experienced psychosocial difficulties. <i>BMC Psychiatry</i> , 2012, 12, 193.	1.1	118
114	Personal and Social Performance (PSP) scale for patients with schizophrenia: translation to Portuguese, cross-cultural adaptation and interrater reliability. <i>Jornal Brasileiro De Psiquiatria</i> , 2012, 61, 176-180.	0.2	7
115	Respiratory Variability during Different Auditory Stimulation Periods in Schizophrenia Patients. <i>Methods of Information in Medicine</i> , 2012, 51, 29-38.	0.7	8
116	Which Nontraditional Outcomes Should Be Measured in Healthcare Decision-Making in Schizophrenia? A Systematic Review. <i>Perspectives in Psychiatric Care</i> , 2012, 48, 198-207.	0.9	8
117	Core dysfunction in schizophrenia: electrophysiology trait biomarkers. <i>Acta Psychiatrica Scandinavica</i> , 2012, 126, 59-71.	2.2	17
118	Early prodromal symptoms can predict future psychosis in familial high-risk youth. <i>Journal of Psychiatric Research</i> , 2012, 46, 105-110.	1.5	46
119	Behavioural alterations relevant to developmental brain disorders in mice with neonatally induced ventral hippocampal lesions. <i>Brain Research Bulletin</i> , 2013, 94, 71-81.	1.4	22
120	Impaired gesture performance in schizophrenia: Particular vulnerability of meaningless pantomimes. <i>Neuropsychologia</i> , 2013, 51, 2674-2678.	0.7	55

#	ARTICLE	IF	CITATIONS
121	2742 – A prospective comparative study of risperidone long-acting injection for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. <i>European Psychiatry</i> , 2013, 28, 1.	0.1	0
122	Unraveling the relationship between obesity, schizophrenia and cognition. <i>Schizophrenia Research</i> , 2013, 151, 107-112.	1.1	32
123	Does change in definition of psychotic symptoms in diagnosis of schizophrenia in DSM-5 affect caseness?. <i>Asian Journal of Psychiatry</i> , 2013, 6, 330-332.	0.9	23
124	Circular inferences in schizophrenia. <i>Brain</i> , 2013, 136, 3227-3241.	3.7	153
125	Postmortem analysis of cardiovascular deaths in schizophrenia: A 10-year review. <i>Schizophrenia Research</i> , 2013, 150, 398-403.	1.1	40
126	Management of schizophrenia: clinical experience with asenapine. <i>Journal of Psychopharmacology</i> , 2013, 27, 14-22.	2.0	10
127	Renaming schizophrenia: Keeping up with the facts. <i>Schizophrenia Research</i> , 2013, 148, 1-2.	1.1	23
128	Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. <i>BMC Psychiatry</i> , 2013, 13, 241.	1.1	10
129	Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. <i>BMC Psychiatry</i> , 2013, 13, 261.	1.1	61
130	Examination of categorical approach to symptom assessment: cross-validation of fouldsâ€™™ Delusions-Symptoms-States Inventory with Korean non-patient and patient groups. <i>BMC Psychiatry</i> , 2013, 13, 251.	1.1	5
131	Definition and description of schizophrenia in the DSM-5. <i>Schizophrenia Research</i> , 2013, 150, 3-10.	1.1	491
132	Balzac's Louis Lambert: Schizophrenia before Kraepelin and Bleuler. <i>Frontiers of Neurology and Neuroscience</i> , 2013, 31, 10-34.	3.0	0
133	Serum testosterone levels are related to cognitive function in men with schizophrenia. <i>Psychoneuroendocrinology</i> , 2013, 38, 1717-1728.	1.3	70
134	Dihydrothiazolopyridone Derivatives as a Novel Family of Positive Allosteric Modulators of the Metabotropic Glutamate 5 (mGlu ₅) Receptor. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7243-7259.	2.9	20
135	Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitergic pathways. <i>Journal of Psychopharmacology</i> , 2013, 27, 1032-1043.	2.0	105
136	Evidence of a dimensional relationship between schizotypy and schizophrenia: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 317-327.	2.9	255
137	Early detection, early symptom progression and symptomatic remission after ten years in a first episode of psychosis study. <i>Schizophrenia Research</i> , 2013, 143, 337-343.	1.1	41
138	Scale for the Assessment of Negative Symptoms structure in first episode psychosis. <i>Psychiatry Research</i> , 2013, 210, 1191-1197.	1.7	35

#	ARTICLE	IF	CITATIONS
139	Association study of Neuregulin-1 gene polymorphisms in a north Indian schizophrenia sample. <i>Schizophrenia Research</i> , 2013, 144, 24-30.	1.1	36
141	Analysis of Sp transcription factors in the postmortem brain of chronic schizophrenia: A pilot study of relationship to negative symptoms. <i>Journal of Psychiatric Research</i> , 2013, 47, 926-934.	1.5	39
142	Prevention and Recovery in Early Psychosis (PREPÂ®): Building a public-academic partnership program in Massachusetts, United States. <i>Asian Journal of Psychiatry</i> , 2013, 6, 171-177.	0.9	23
143	Some recent kernels of knowledge from the <i>Indian Journal of Psychiatry</i> . <i>Asian Journal of Psychiatry</i> , 2013, 6, 90.	0.9	1
144	25 years of editing <i>Schizophrenia Research</i> : A unique and gratifying journey. <i>Schizophrenia Research</i> , 2013, 143, 1-2.	1.1	4
145	Impaired pantomime in schizophrenia: Association with frontal lobe function. <i>Cortex</i> , 2013, 49, 520-527.	1.1	62
146	NMDA-receptor coagonists in serum, plasma, and cerebrospinal fluid of schizophrenia patients: A meta-analysis of caseâ€“control studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1587-1596.	2.9	31
147	An updated overview of animal models in neuropsychiatry. <i>Neuroscience</i> , 2013, 240, 204-218.	1.1	36
148	Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study. <i>Schizophrenia Research and Treatment</i> , 2013, 2013, 1-7.	0.7	6
149	Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin. <i>Clinical Pharmacokinetics</i> , 2013, 52, 673-683.	1.6	14
150	Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: Relevance to DSM-5. <i>Schizophrenia Research</i> , 2013, 150, 15-20.	1.1	165
151	Genetic models of schizophrenia and related psychotic disorders: progress and pitfalls across the methodological â€œminefieldâ€. <i>Cell and Tissue Research</i> , 2013, 354, 247-257.	1.5	10
152	Developmental neuroinflammation and schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 42, 20-34.	2.5	258
153	Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: A preliminary study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 45, 144-149.	2.5	37
154	Orbitofrontal cortex abnormality and deficit schizophrenia. <i>Schizophrenia Research</i> , 2013, 143, 246-252.	1.1	72
155	A further evaluation of decision-making under risk and under ambiguity in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 249-257.	1.8	53
156	New Animal Models of Progressive Neurodegeneration: Tools for Developing Predictive Diagnostics and Identifying Presymptomatic Therapeutic Targets. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2013, , 45-68.	0.6	1
157	A protective-compensatory model may reconcile the genetic and the developmental findings in schizophrenia. <i>Schizophrenia Research</i> , 2013, 144, 9-15.	1.1	21

#	ARTICLE	IF	CITATIONS
158	Psychotic disorders in DSM-5. Asian Journal of Psychiatry, 2013, 6, 266-268.	0.9	35
159	Characterization of gene-environment interactions by behavioral profiling of selectively bred rats: The effect of NMDA receptor inhibition and social isolation. Behavioural Brain Research, 2013, 240, 134-145.	1.2	31
160	Administration of the Y2 Receptor Agonist PYY3-36 in Mice Induces Multiple Behavioral Changes Relevant to Schizophrenia. Neuropsychopharmacology, 2013, 38, 2446-2455.	2.8	29
161	The Effect of an Alternative Term for Schizophrenia in Reducing Discriminatory Attitudes of the English-Speaking Lay Public. International Journal of Mental Health, 2013, 42, 3-33.	0.5	2
162	A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia. Neuropsychopharmacology, 2013, 38, 968-975.	2.8	170
163	Metabolic syndrome in schizophrenia: Theoretical, clinical and translational perspectives. Indian Journal of Psychological Medicine, 2013, 35, 117-120.	0.6	4
164	Schizophrenia Spectrum and Other Psychotic Disorders. Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies, 2013, 48, 33-39.	0.1	3
165	Schizophrenia Spectrum and Other Psychotic Disorders. Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies, 2013, 48, 40.	0.1	0
166	Early Intervention and the Treatment of Prodrome in Schizophrenia. Journal of Psychiatric Practice, 2013, 19, 375-385.	0.3	12
167	The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Therapeutic Advances in Psychopharmacology, 2013, 3, 33-51.	1.2	90
168	Diagnostic trajectory, interplay and convergence/divergence across all 12 DSM-IV psychotic diagnoses: 6-year follow-up of the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS). Psychological Medicine, 2013, 43, 2523-2533.	2.7	27
169	Quantitative Psychomotor Dysfunction in Schizophrenia: A Loss of Drive, Impaired Movement Execution or Both?. Neuropsychobiology, 2013, 68, 221-227.	0.9	42
170	Disruption of Arp2/3 Results in Asymmetric Structural Plasticity of Dendritic Spines and Progressive Synaptic and Behavioral Abnormalities. Journal of Neuroscience, 2013, 33, 6081-6092.	1.7	157
171	The Challenge of Adherence in Schizophrenia. , 2013, , .		0
172	Peer support for schizophrenia. The Cochrane Library, 2013, , .	1.5	3
173	Is a Schizo-Obsessive Subtype Associated With Cognitive Impairment?. Journal of Nervous and Mental Disease, 2013, 201, 30-35.	0.5	19
174	Research in young people at ultra-high risk for psychosis: a review of the current evidence. Irish Journal of Psychological Medicine, 2013, 30, 77-89.	0.7	6
176	Obsessive-compulsive symptoms in schizophrenia: epidemiological and clinical aspects. , 0, , 33-56.		0

#	ARTICLE	IF	CITATIONS
177	Unheard Voices: Mothers of Adult Children With Schizophrenia Speak Up. <i>Canadian Journal of Community Mental Health</i> , 2013, 32, 109-120.	0.1	4
178	Adherence Challenges and Long-Acting Injectable Antipsychotic Treatment in Patients with Schizophrenia. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2013, 51, 13-18.	0.3	16
179	A randomized controlled trial with a Canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia. <i>Frontiers in Pharmacology</i> , 2013, 4, 100.	1.6	26
180	Aberrant neural synchrony in the maternal immune activation model: using translatable measures to explore targeted interventions. <i>Frontiers in Behavioral Neuroscience</i> , 2013, 7, 217.	1.0	31
182	Schizophrenia Spectrum Disorder in DSM-5 : Is this a New Change?. <i>Korean Journal of Schizophrenia Research</i> , 2014, 17, 5.	0.3	1
183	Temporomandibular disorders in patients with schizophrenia using antipsychotic agents: a discussion paper. <i>Drug, Healthcare and Patient Safety</i> , 2014, 6, 21.	1.0	6
184	The Concept of Schizophrenia: From Unity to Diversity. <i>Advances in Psychiatry</i> , 2014, 2014, 1-39.	0.4	7
185	A Critical Review of Pro-Cognitive Drug Targets in Psychosis: Convergence on Myelination and Inflammation. <i>Frontiers in Psychiatry</i> , 2014, 5, 11.	1.3	35
186	Reduced Expression of Nogo-A Leads to Motivational Deficits in Rats. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 10.	1.0	17
187	Drosophila model of cognitive disorders: Focus on memory abnormality. , 0, , 162-176.		0
188	Pro-/Anti-inflammatory Dysregulation in Patients With First Episode of Psychosis: Toward an Integrative Inflammatory Hypothesis of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2014, 40, 376-387.	2.3	156
190	Negative Symptoms in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2014, 8, 28-35B.	1.4	19
191	Antipsychotic dosing: found in translation. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, 223-231.	1.4	13
192	Schizophrenia and Other Psychotic Disorders in Diagnostic and Statistical Manual of Mental Disorders (DSM)-5: Clinical Implications of Revisions from DSM-IV. <i>Indian Journal of Psychological Medicine</i> , 2014, 36, 223-225.	0.6	24
193	Premorbid adjustment profiles in psychosis and the role of familial factors.. <i>Journal of Abnormal Psychology</i> , 2014, 123, 578-587.	2.0	12
195	Longitudinal Evaluation of the Psychomotor Syndrome in Schizophrenia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2014, 26, 359-368.	0.9	14
196	Revisions and refinements of the diagnosis of schizophrenia in DSM-5.. <i>Clinical Psychology: Science and Practice</i> , 2014, 21, 236-244.	0.6	5
197	Swan song for schizophrenia?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 302-305.	1.3	21

#	ARTICLE	IF	CITATIONS
198	Risk and protective factors for relapse among Individuals with Schizophrenia: A Qualitative Study in Dar es Salaam, Tanzania. <i>BMC Psychiatry</i> , 2014, 14, 240.	1.1	42
199	Social and functional capacity of schizophrenia patients: A cross-sectional study. <i>International Journal of Social Psychiatry</i> , 2014, 60, 352-358.	1.6	9
200	The Active Therapeutic Processes of Acceptance and Commitment Therapy for Persistent Symptoms of Psychosis: Clients' Perspectives. <i>Behavioural and Cognitive Psychotherapy</i> , 2014, 42, 402-420.	0.9	30
201	Less Structured Movement Patterns Predict Severity of Positive Syndrome, Excitement, and Disorganization. <i>Schizophrenia Bulletin</i> , 2014, 40, 585-591.	2.3	114
202	Therapeutic potentials of mind-body interventions for psychosis. <i>Clinical Practice (London, England)</i> , 2014, 11, 677-688.	0.1	3
203	How much do we know about schizophrenia and how well do we know it? Evidence from the Schizophrenia Library. <i>Psychological Medicine</i> , 2014, 44, 3387-3405.	2.7	23
204	The neurobiology of relapse in schizophrenia. <i>Schizophrenia Research</i> , 2014, 152, 381-390.	1.1	30
205	Frontal gamma noise power and cognitive domains in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2014, 221, 104-113.	0.9	20
206	The PSD protein ProSAP2/Shank3 displays synapto-nuclear shuttling which is deregulated in a schizophrenia-associated mutation. <i>Experimental Neurology</i> , 2014, 253, 126-137.	2.0	59
207	Prenatal Poly(I:C) Exposure and Other Developmental Immune Activation Models in Rodent Systems. <i>Biological Psychiatry</i> , 2014, 75, 307-315.	0.7	514
208	What are the similarities and differences between schizophrenia and schizophrenia-like psychosis of epilepsy? A neuropathological approach to the understanding of schizophrenia spectrum and epilepsy. <i>Epilepsy and Behavior</i> , 2014, 38, 143-147.	0.9	11
209	Increased stability of microtubules in cultured olfactory neuroepithelial cells from individuals with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 48, 252-258.	2.5	29
210	Antibodies Directed to the Gram-Negative Bacterium <i>Neisseria gonorrhoeae</i> Cross-React with the 60kDa Heat Shock Protein and Lead to Impaired Neurite Outgrowth in NTERA2/D1 Cells. <i>Journal of Molecular Neuroscience</i> , 2014, 54, 125-136.	1.1	6
211	Antibodies Directed to <i>Neisseria gonorrhoeae</i> Impair Nerve Growth Factor-Dependent Neurite Outgrowth in Rat PC12 Cells. <i>Journal of Molecular Neuroscience</i> , 2014, 52, 353-365.	1.1	6
212	Negative symptoms of schizophrenia: Clinical features, relevance to real world functioning and specificity versus other CNS disorders. <i>European Neuropsychopharmacology</i> , 2014, 24, 693-709.	0.3	171
213	The effects of juvenile capsaicin desensitization in rats: Behavioral impairments. <i>Physiology and Behavior</i> , 2014, 125, 38-44.	1.0	11
214	Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or Δ^9 -tetrahydrocannabinol (THC). <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 52, 53-69.	2.5	56
216	Mood Instability and Psychosis: Analyses of British National Survey Data. <i>Schizophrenia Bulletin</i> , 2014, 40, 269-277.	2.3	99

#	ARTICLE	IF	CITATIONS
217	Abnormal Dynamics of EEG Oscillations in Schizophrenia Patients on Multiple Time Scales. <i>IEEE Transactions on Biomedical Engineering</i> , 2014, 61, 1756-1764.	2.5	44
218	The nature of the relationship of psychomotor slowing with negative symptomatology in schizophrenia. <i>Cognitive Neuropsychiatry</i> , 2014, 19, 36-46.	0.7	39
219	Antipsychotic treatment of schizophrenia: An update. <i>Asian Journal of Psychiatry</i> , 2014, 11, 3-7.	0.9	69
220	Insights from Proteomic Studies on Schizophrenia Preclinical Models: What Can We Learn for Drug Discovery?. <i>Advances in Biological Psychiatry</i> , 2014, , 56-73.	0.2	1
221	Association of aberrant neural synchrony and altered GAD67 expression following exposure to maternal immune activation, a risk factor for schizophrenia. <i>Translational Psychiatry</i> , 2014, 4, e418-e418.	2.4	50
222	Discovery of a Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitor for the Potential Treatment of Schizophrenia. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4196-4212.	2.9	36
223	CDP-choline: Effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression. <i>Journal of Psychopharmacology</i> , 2014, 28, 1095-1108.	2.0	24
224	P-glycoprotein activity in the blood-brain barrier is affected by virus-induced neuroinflammation and antipsychotic treatment. <i>Neuropharmacology</i> , 2014, 85, 548-553.	2.0	7
226	Functional characterization of FABP3, 5 and 7 gene variants identified in schizophrenia and autism spectrum disorder and mouse behavioral studies. <i>Human Molecular Genetics</i> , 2014, 23, 6495-6511.	1.4	81
227	Distribution of tract deficits in schizophrenia. <i>BMC Psychiatry</i> , 2014, 14, 99.	1.1	43
228	The synapse in schizophrenia. <i>European Journal of Neuroscience</i> , 2014, 39, 1059-1067.	1.2	53
229	Increase of circulating BDNF levels and its relation to improvement of physical fitness following 12 weeks of combined exercise in chronic patients with schizophrenia: A pilot study. <i>Psychiatry Research</i> , 2014, 220, 792-796.	1.7	56
230	Predictors of disability: A 5-year cohort study of first-episode schizophrenia. <i>Asian Journal of Psychiatry</i> , 2014, 9, 45-50.	0.9	19
231	Genetically modified mice related to schizophrenia and other psychoses: Seeking phenotypic insights into the pathobiology and treatment of negative symptoms. <i>European Neuropsychopharmacology</i> , 2014, 24, 800-821.	0.3	13
232	A latent profile analysis of schizotypy, temperament and character in a nonclinical population: Association with neurocognition. <i>Journal of Psychiatric Research</i> , 2014, 48, 56-64.	1.5	32
233	An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. <i>Schizophrenia Research</i> , 2014, 152, 450-457.	1.1	155
234	A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – Results from the CandleLyte study. <i>European Neuropsychopharmacology</i> , 2014, 24, 1024-1036.	0.3	80
235	A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. <i>Schizophrenia Research</i> , 2014, 155, 52-58.	1.1	48

#	ARTICLE	IF	CITATIONS
236	Cerebral white matter abnormalities and their associations with negative but not positive symptoms of schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2014, 222, 52-59.	0.9	39
237	Aripiprazole (ABILIFY MAINTENA [®]): A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia. <i>Drugs</i> , 2014, 74, 1097-1110.	4.9	34
238	Multitasking capacities in persons diagnosed with schizophrenia: A preliminary examination of their neurocognitive underpinnings and ability to predict real world functioning. <i>Psychiatry Research</i> , 2014, 217, 163-170.	1.7	17
241	Effectiveness of progressive muscle relaxation training for adults diagnosed with schizophrenia: a systematic review protocol. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2014, 12, 85-97.	1.7	1
242	Ethnicity moderates the effects of resources on quality of life for persons with mental illness living in community settings.. <i>Psychiatric Rehabilitation Journal</i> , 2014, 37, 309-315.	0.8	5
243	Horticultural therapy for schizophrenia. <i>The Cochrane Library</i> , 2014, , CD009413.	1.5	10
244	Cognitive performance during the first year of treatment in first-episode schizophrenia: a caseâ€“control study. <i>Psychological Medicine</i> , 2015, 45, 2873-2883.	2.7	29
245	Illness course and quality of life in Mexican patients with psychosis. <i>Revista De PsiquiatrÃa Y Salud Mental (English Edition)</i> , 2015, 8, 218-223.	0.2	0
246	La mÃ©thodologie de la thÃ©orisation enracinÃ©e constructiviste pour une perspective nouvelle et nÃ©cessaire de lâ€™adaptation des personnes vivant avec la schizophrÃ©nie. <i>Approches Inductives</i> , 0, 2, 39-67.	0.1	2
247	White matter alterations in first episode treatment-naÃ¯ve patients with deficit schizophrenia: a combined VBM and DTI study. <i>Scientific Reports</i> , 2015, 5, 12994.	1.6	42
248	Effective connectivity during episodic memory retrieval in schizophrenia participants before and after antipsychotic medication. <i>Human Brain Mapping</i> , 2015, 36, 1442-1457.	1.9	72
249	Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 865.	1.0	12
250	Smoking in schizophrenic patients: A critique of the self-medication hypothesis. <i>World Journal of Psychiatry</i> , 2015, 5, 35.	1.3	58
251	Una propuesta de actualizaciÃ³n del modelo bio-psico-social para ser aplicado a la esquizofrenia. <i>Revista De La AsociaciÃ³n EspaÃ±ola De NeuropsiquiatrÃa</i> , 2015, 35, 511-526.	0.1	4
252	Abnormal Motor Activity and Thermoregulation in a Schizophrenia Rat Model for Translational Science. <i>PLoS ONE</i> , 2015, 10, e0143751.	1.1	20
253	Nonlinear parameters of surface EMG in schizophrenia patients depend on kind of antipsychotic therapy. <i>Frontiers in Physiology</i> , 2015, 6, 197.	1.3	5
254	Association between Unmet Needs and Clinical Status in Patients with First Episode of Schizophrenia in Chile. <i>Frontiers in Psychiatry</i> , 2015, 6, 57.	1.3	9
255	Structural and functional neuroimaging findings associated with the use of clozapine in schizophrenia: a systematic review. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 71-79.	0.9	15

#	ARTICLE	IF	CITATIONS
256	Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy. <i>BioMed Research International</i> , 2015, 2015, 1-21.	0.9	103
257	Developmental Immune Activation Models with Relevance to Schizophrenia. <i>Current Topics in Neurotoxicity</i> , 2015, , 15-32.	0.4	2
258	Social-Cognitive Deficits in Schizophrenia. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 30, 397-409.	0.8	40
259	Trends in diagnosis of bipolar disorder: Have the boundaries changed?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 1021-1028.	1.3	8
260	Dissecting negative symptoms in schizophrenia: Opportunities for translation into new treatments. <i>Journal of Psychopharmacology</i> , 2015, 29, 116-126.	2.0	44
261	Should the label "schizophrenia" be abandoned?. <i>Schizophrenia Research</i> , 2015, 162, 276-284.	1.1	98
262	S-SCAM, A Rare Copy Number Variation Gene, Induces Schizophrenia-Related Endophenotypes in Transgenic Mouse Model. <i>Journal of Neuroscience</i> , 2015, 35, 1892-1904.	1.7	19
263	A systematic review of the antipsychotic properties of cannabidiol in humans. <i>Schizophrenia Research</i> , 2015, 162, 153-161.	1.1	200
264	What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 107-116.	1.8	26
265	A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 51, 15-30.	2.9	119
266	N-bridged 5,6-bicyclic pyridines: Recent applications in central nervous system disorders. <i>European Journal of Medicinal Chemistry</i> , 2015, 97, 719-731.	2.6	18
267	Sex-specific alterations in behavioral and cognitive functions in a three hit animal model of schizophrenia. <i>Behavioural Brain Research</i> , 2015, 284, 85-93.	1.2	27
268	Molecular modeling and docking study on dopamine D2-like and serotonin 5-HT2A receptors. <i>Journal of Molecular Graphics and Modelling</i> , 2015, 57, 143-155.	1.3	20
269	Estimation of nonlinear measures of schizophrenia patients' EEG in emotional states. <i>Irbm</i> , 2015, 36, 250-258.	3.7	6
270	Cumulative stress pathophysiology in schizophrenia as indexed by allostatic load. <i>Psychoneuroendocrinology</i> , 2015, 60, 120-129.	1.3	48
271	Psychiatric Autoimmunity: N-Methyl-d-Aspartate Receptor IgG and Beyond. <i>Psychosomatics</i> , 2015, 56, 227-241.	2.5	44
272	The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization. <i>Schizophrenia Research</i> , 2015, 166, 69-79.	1.1	20
273	Altered threat and safety neural processing linked to persecutory delusions in schizophrenia: a two-task fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2015, 233, 352-366.	0.9	17

#	ARTICLE	IF	CITATIONS
274	Effects of selective estrogen receptor alpha and beta modulators on prepulse inhibition in male mice. <i>Psychopharmacology</i> , 2015, 232, 2981-2994.	1.5	14
275	Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia. <i>BMC Neuroscience</i> , 2015, 16, 9.	0.8	29
276	Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders. , 2015, , 233-271.		3
277	Psychomotor symptoms of schizophrenia map on the cerebral motor circuit. <i>Psychiatry Research - Neuroimaging</i> , 2015, 233, 293-298.	0.9	84
278	Challenges for group leaders working with families dealing with early psychosis: a qualitative study. <i>BMC Psychiatry</i> , 2015, 15, 141.	1.1	9
279	Phenomenology and neurobiology of self disorder in schizophrenia: Secondary factors. <i>Schizophrenia Research</i> , 2015, 169, 474-482.	1.1	42
280	Cross-cultural adaptation of the Schizophrenia Caregiver Questionnaire (SCQ) and the Caregiver Global Impression (CaGI) Scales in 11 languages. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 76.	1.0	9
281	Suicidality in Schizophrenia Spectrum Disorders: The Relationship to Hallucinations and Persecutory Delusions. <i>European Psychiatry</i> , 2015, 30, 830-836.	0.1	77
282	Cognitive structure from childhood to adulthood in kindreds densely affected by schizophrenia and bipolar disorder. <i>Psychiatry Research</i> , 2015, 229, 101-108.	1.7	1
283	Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia. <i>Schizophrenia Research</i> , 2015, 166, 304-309.	1.1	26
285	Phosphodiesterase 10A inhibitors: analysis of US/EP patents granted since 2012. <i>Pharmaceutical Patent Analyst</i> , 2015, 4, 161-186.	0.4	9
286	The impact of obsessive dimension on symptoms and functioning in schizophrenia. <i>Psychiatry Research</i> , 2015, 230, 581-584.	1.7	14
287	Abnormal contextâ€“reward associations in an immune-mediated neurodevelopmental mouse model with relevance to schizophrenia. <i>Translational Psychiatry</i> , 2015, 5, e637-e637.	2.4	20
288	Phenomenology and neurobiology of self disorder in schizophrenia: Primary factors. <i>Schizophrenia Research</i> , 2015, 169, 464-473.	1.1	55
289	Dendritic spine alterations in schizophrenia. <i>Neuroscience Letters</i> , 2015, 601, 46-53.	1.0	132
290	Decrease in olfactory and taste receptor expression in the dorsolateral prefrontal cortex in chronic schizophrenia. <i>Journal of Psychiatric Research</i> , 2015, 60, 109-116.	1.5	57
291	Co-occurring Addictive and Psychiatric Disorders. , 2015, , .		13
292	Curso de la enfermedad y calidad de vida en pacientes mexicanos con psicosis. <i>Revista De PsiquiatrÃa Y Salud Mental</i> , 2015, 8, 218-223.	1.0	2

#	ARTICLE	IF	CITATIONS
293	Dysconnectivity Within the Default Mode in First-Episode Schizophrenia: A Stochastic Dynamic Causal Modeling Study With Functional Magnetic Resonance Imaging. <i>Schizophrenia Bulletin</i> , 2015, 41, 144-153.	2.3	84
294	Common Variants in the MKL1 Gene Confer Risk of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 715-727.	2.3	15
295	Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models. <i>Schizophrenia Bulletin</i> , 2015, 41, 879-891.	2.3	71
296	MMPs: a novel drug target for schizophrenia. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 77-85.	1.5	30
297	Analysis of heart rate variability during auditory stimulation periods in patients with schizophrenia. <i>Journal of Clinical Monitoring and Computing</i> , 2015, 29, 153-162.	0.7	26
298	The Microbiota and Gut-Brain Axis: Contributions to the Immunopathogenesis of Schizophrenia. <i>Current Pharmaceutical Design</i> , 2016, 22, 6122-6133.	0.9	39
299	Modeling Schizophrenia in Animals. , 2016, , 353-381.		0
300	Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 99.	1.0	12
302	Quality of life and physical activity levels in outpatients with schizophrenia. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 157-160.	0.9	16
303	Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 2.6 68		
304	Factors Predicting Personal and Social Performance in Schizophrenia Patients. <i>Korean Journal of Schizophrenia Research</i> , 2016, 19, 47.	0.3	3
305	Arterial spin labeling in patients with schizophrenia: a systematic review. <i>Revista De Psiquiatria Clinica</i> , 2016, 43, 151-156.	0.6	10
306	Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials. <i>Mediators of Inflammation</i> , 2016, 2016, 1-8.	1.4	30
307	Abnormal Sense of Agency in Patients with Schizophrenia: Evidence from Bimanual Coupling Paradigm. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 43.	1.0	46
308	From Linkage Studies to Epigenetics: What We Know and What We Need to Know in the Neurobiology of Schizophrenia. <i>Frontiers in Neuroscience</i> , 2016, 10, 202.	1.4	34
309	DNA Damage and Repair in Schizophrenia and Autism: Implications for Cancer Comorbidity and Beyond. <i>International Journal of Molecular Sciences</i> , 2016, 17, 856.	1.8	66
310	Inferring the Dysconnection Syndrome in Schizophrenia: Interpretational Considerations on Methods for the Network Analyses of fMRI Data. <i>Frontiers in Psychiatry</i> , 2016, 7, 132.	1.3	31
311	Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 1261.	1.0	12

#	ARTICLE	IF	CITATIONS
312	AYURVEDIC MANAGEMENT OF SCHIZOPHRENIA: REPORT OF TWO CASES. International Research Journal of Pharmacy, 2016, 7, 41-44.	0.0	1
313	Social and nonsocial affective processing in schizophrenia – An ERP study. International Journal of Psychophysiology, 2016, 107, 54-62.	0.5	10
314	Neurological soft signs in patients with schizophrenia: current knowledge and future perspectives in the post-genomics era. Translational Developmental Psychiatry, 2016, 4, 30071.	0.3	6
315	Developmental restoration of LTP deficits in heterozygous CaMKII β KO mice. Journal of Neurophysiology, 2016, 116, 2140-2151.	0.9	9
316	Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations. Journal of Market Access & Health Policy, 2016, 4, 30725.	0.8	4
318	Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia. Scientific Reports, 2016, 6, 38897.	1.6	135
319	Acetylcholinergic Nicotinic Receptors as Pharmacological Targets for Cognitive Enhancement: Emerging Evidence from Psychosis Populations. , 2016, , 707-730.		0
320	Maternal immune activation produces neonatal excitability defects in offspring hippocampal neurons from pregnant rats treated with poly I:C. Scientific Reports, 2016, 6, 19106.	1.6	41
321	Basic symptoms in schizophrenia, their clinical study and relevance in research. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2016, 9, 111-122.	0.2	4
322	Asperger Syndrome and Schizophrenia: A Comparative Neuropsychological Study. Journal of Autism and Developmental Disorders, 2016, 46, 2292-2304.	1.7	21
323	NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis?. Trends in Neurosciences, 2016, 39, 300-310.	4.2	73
324	Synthesis, structure–activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3141-3147.	1.0	6
325	Childhood pegboard task predicts adult-onset psychosis-spectrum disorder among a genetic high-risk sample. Schizophrenia Research, 2016, 178, 68-73.	1.1	5
326	Phenotypes associated with psychiatric disorders are sex-specific in a mutant mouse line. Brain Research, 2016, 1652, 53-61.	1.1	4
327	Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatrica Scandinavica, 2016, 133, 5-22.	2.2	72
328	Toxoplasma gondii infection in schizophrenia and associated clinical features. Psychiatry Research, 2016, 245, 327-332.	1.7	34
329	Disability and recovery in schizophrenia: a systematic review of cognitive behavioral therapy interventions. BMC Psychiatry, 2016, 16, 228.	1.1	38
330	Intake of 7,8-Dihydroxyflavone During Juvenile and Adolescent Stages Prevents Onset of Psychosis in Adult Offspring After Maternal Immune Activation. Scientific Reports, 2016, 6, 36087.	1.6	43

#	ARTICLE	IF	CITATIONS
331	Antisera against <i>Neisseria gonorrhoeae</i> cross-react with specific brain proteins of the common marmoset monkey and other nonhuman primate species. <i>Brain Research</i> , 2016, 1653, 23-38.	1.1	5
332	Anatomical and Functional Brain Network Architecture in Schizophrenia. , 2016, , 313-336.		1
333	Schizophrenia and oral health: Review of the literature. <i>Balkan Journal of Dental Medicine</i> , 2016, 20, 15-21.	0.2	7
334	Conceptualizing psychotic disorders: don't throw the baby out with the bathwater. <i>World Psychiatry</i> , 2016, 15, 133-134.	4.8	4
335	Resilience in Patients With Recent Diagnosis of a Schizophrenia Spectrum Disorder. <i>Journal of Nervous and Mental Disease</i> , 2016, 204, 578-584.	0.5	21
336	The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. <i>BMC Psychiatry</i> , 2016, 16, 60.	1.1	54
337	Effect of folic acid on oxidative stress and behavioral changes in the animal model of schizophrenia induced by ketamine. <i>Journal of Psychiatric Research</i> , 2016, 81, 23-35.	1.5	27
338	Deep brain stimulation improves behavior and modulates neural circuits in a rodent model of schizophrenia. <i>Experimental Neurology</i> , 2016, 283, 142-150.	2.0	48
339	Identifying grey matter changes in schizotypy using partial least squares correlation. <i>Cortex</i> , 2016, 81, 137-150.	1.1	26
340	Task-independent effects are potential confounders in longitudinal imaging studies of learning in schizophrenia. <i>NeuroImage: Clinical</i> , 2016, 10, 159-171.	1.4	2
341	Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. <i>Psychopharmacology</i> , 2016, 233, 2663-2674.	1.5	29
342	Cognitive remediation in schizophreniaâ€”The view from India. <i>Asian Journal of Psychiatry</i> , 2016, 22, 124-128.	0.9	7
343	Neuropharmacology of altered brain oscillations in schizophrenia. <i>International Journal of Psychophysiology</i> , 2016, 103, 62-68.	0.5	17
345	A feasibility study of a new computerised cognitive remediation for young adults with schizophrenia. <i>Neuropsychological Rehabilitation</i> , 2016, 26, 321-344.	1.0	17
346	A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. <i>Journal of Psychopharmacology</i> , 2016, 30, 69-77.	2.0	43
347	Platelet serotonin concentration and depressive symptoms in patients with schizophrenia. <i>Psychiatry Research</i> , 2016, 239, 105-110.	1.7	29
348	Psychopathological Symptoms Assessed by a System-Specific Approach Are Related to Global Functioning in Schizophrenic Disorders. <i>Psychopathology</i> , 2016, 49, 77-82.	1.1	7
349	Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 395-407.	0.9	13

#	ARTICLE	IF	CITATIONS
350	European Psychiatric Association (EPA) guidance on the quality of eMental health interventions in the treatment of psychotic disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 125-137.	1.8	47
351	Obsessive-compulsive symptoms interact with disorganization in influencing social functioning in schizophrenia. <i>Schizophrenia Research</i> , 2016, 171, 35-41.	1.1	18
352	The profile of psychiatric symptoms exacerbated by methamphetamine use. <i>Drug and Alcohol Dependence</i> , 2016, 161, 104-109.	1.6	64
353	Elucidating the role of Early Maladaptive Schemas for psychotic symptomatology. <i>Psychiatry Research</i> , 2016, 238, 53-59.	1.7	19
354	Disconnection Between Amygdala and Medial Prefrontal Cortex in Psychotic Disorders. <i>Schizophrenia Bulletin</i> , 2016, 42, 1056-1067.	2.3	40
356	Shared and divergent neurocognitive impairments in adult patients with schizophrenia and bipolar disorder: Whither the evidence?. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 61, 66-89.	2.9	40
357	Sex/gender differences in the brain and cognition in schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 67, 57-78.	2.9	195
358	Rewarding yet demanding: client perspectives on enabling occupations during early stages of recovery from schizophrenia. <i>Scandinavian Journal of Occupational Therapy</i> , 2016, 23, 97-106.	1.1	13
359	La schizophr�nie dans le DSM-5. <i>Annales Medico-Psychologiques</i> , 2016, 174, 672-676.	0.2	1
360	Using human brain imaging studies as a guide toward animal models of schizophrenia. <i>Neuroscience</i> , 2016, 321, 77-98.	1.1	26
361	Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2016, 42, 335-343.	2.3	78
362	Developmental Trajectories of Auditory Cortex Synaptic Structures and Gap-Prepulse Inhibition of Acoustic Startle Between Early Adolescence and Young Adulthood in Mice. <i>Cerebral Cortex</i> , 2016, 26, 2115-2126.	1.6	17
363	Evidence that communication impairment in schizophrenia is associated with generalized poor task performance. <i>Psychiatry Research</i> , 2017, 249, 172-179.	1.7	13
364	Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2017, 10, 4-20.	1.0	18
365	Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: Pathophysiological and phenotypic implications. <i>Schizophrenia Research</i> , 2017, 188, 98-109.	1.1	47
366	Functioning in patients with schizophrenia: a systematic review of the literature using the International Classification of Functioning, Disability and Health (ICF) as a reference. <i>Quality of Life Research</i> , 2017, 26, 531-543.	1.5	20
367	Metabolic syndrome and cardiovascular risk among institutionalized patients with schizophrenia receiving long term tertiary care. <i>Comprehensive Psychiatry</i> , 2017, 74, 196-203.	1.5	21
368	Mental health-related stigma and pathways to care for people at risk of psychotic disorders or experiencing first-episode psychosis: a systematic review. <i>Psychological Medicine</i> , 2017, 47, 1867-1879.	2.7	108

#	ARTICLE	IF	CITATIONS
369	Exploration of food addiction in people living with schizophrenia. <i>Asian Journal of Psychiatry</i> , 2017, 27, 81-84.	0.9	12
370	Dopamine, cognitive biases and assessment of certainty: A neurocognitive model of delusions. <i>Clinical Psychology Review</i> , 2017, 54, 96-106.	6.0	55
371	Depressive symptoms in schizophrenia and dopamine and serotonin gene polymorphisms. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 77, 209-215.	2.5	31
372	Detecting synaptic autoantibodies in psychoses: need for more sensitive methods. <i>Current Opinion in Neurology</i> , 2017, 30, 317-326.	1.8	3
373	Crossreactivity of an Antiserum Directed to the Gram-Negative Bacterium <i>Neisseria gonorrhoeae</i> with the SNARE-Complex Protein Snap23 Correlates to Impaired Exocytosis in SH-SY5Y Cells. <i>Journal of Molecular Neuroscience</i> , 2017, 62, 163-180.	1.1	6
374	Labeling and defining severe and enduring anorexia nervosa: A systematic review and critical analysis. <i>International Journal of Eating Disorders</i> , 2017, 50, 611-623.	2.1	71
375	Investigational dopamine antagonists for the treatment of schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 687-698.	1.9	18
376	Exercise Treatments for Psychosis: a Review. <i>Current Treatment Options in Psychiatry</i> , 2017, 4, 152-166.	0.7	50
377	Schizophrenia in mid-adulthood after prenatal exposure to the Chinese Famine of 1959–1961. <i>Schizophrenia Research</i> , 2017, 184, 21-25.	1.1	18
378	Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 639-648.	0.6	29
379	Challenges and opportunities for the development of new antipsychotic drugs. <i>Biochemical Pharmacology</i> , 2017, 143, 10-24.	2.0	25
380	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2017, 10, 4-20.	0.2	7
381	Innovations in first episode psychosis interventions: The case for a "RAISE-Plus" approach. <i>Schizophrenia Research</i> , 2017, 182, 2-3.	1.1	26
382	Hypothesis: Exosomal microRNAs as potential biomarkers for schizophrenia. <i>Medical Hypotheses</i> , 2017, 103, 21-25.	0.8	8
383	Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2017, 964, 153-161.	0.8	51
384	Psychiatric Care in Severe Obesity. , 2017, , .		3
385	Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. <i>British Journal of Psychiatry</i> , 2017, 211, 350-358.	1.7	239
386	PDE Inhibitors for the Treatment of Schizophrenia. <i>Advances in Neurobiology</i> , 2017, 17, 385-409.	1.3	23

#	ARTICLE	IF	CITATIONS
387	Short-range connections in the developmental connectome during typical and atypical brain maturation. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 83, 109-122.	2.9	86
388	A Practical Approach to Avoiding Cardiovascular Adverse Effects of Psychoactive Medications. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1577-1586.	0.8	16
389	Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. <i>British Journal of Pharmacology</i> , 2017, 174, 3173-3190.	2.7	17
390	Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4904-4916.	1.4	11
391	Serum fatty acid patterns in patients with schizophrenia: a targeted metabolomics study. <i>Translational Psychiatry</i> , 2017, 7, e1176-e1176.	2.4	46
392	Effects of oral versus long-acting antipsychotics on social functioning: A psychiatrists' survey in India. <i>Asian Journal of Psychiatry</i> , 2017, 30, 88-93.	0.9	8
393	Cognitive screening and behavioural observation of functional ability in patients with multiple episode schizophrenia: an exploratory study. <i>BMJ Open</i> , 2017, 7, e014783.	0.8	6
394	Healthcare resource use in schizophrenia, EuroSC findings. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1372027.	0.8	8
395	Syntaxin 1B contributes to regulation of the dopaminergic system through GABA transmission in the CNS. <i>European Journal of Neuroscience</i> , 2017, 46, 2867-2874.	1.2	9
396	Checking the predictive accuracy of basic symptoms against ultra high-risk criteria and testing of a multivariable prediction model: Evidence from a prospective three-year observational study of persons at clinical high-risk for psychosis. <i>European Psychiatry</i> , 2017, 45, 27-35.	0.1	21
397	Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain. <i>Journal of Medical Economics</i> , 2017, 20, 1039-1047.	1.0	17
398	Are reprogrammed cells a useful tool for studying dopamine dysfunction in psychotic disorders? A review of the current evidence. <i>European Journal of Neuroscience</i> , 2017, 45, 45-57.	1.2	4
400	Mirror-image study of aripiprazole long-acting injectable for the treatment of psychiatric patients attended in community mental health team. <i>European Neuropsychopharmacology</i> , 2017, 27, S751-S752.	0.3	0
401	Psychosis Risk Syndrome: What Now?. <i>Journal of Psychiatric Practice</i> , 2017, 23, 415-424.	0.3	3
402	Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2935-2943.	1.0	15
403	Sensing the Worst: Neurophenomenological Perspectives on Neutral Stimuli Misperception in Schizophrenia Spectrum. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 269.	1.0	4
404	Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2021-2035.	1.0	9
405	Cultural adaptation and validity of the Malay version of the brief psychiatric rating scale (BPRS-M) among patients with schizophrenia in a psychiatric clinic. <i>BMC Psychiatry</i> , 2017, 17, 384.	1.1	9

#	ARTICLE	IF	CITATIONS
406	Correlation of DRD2 mRNA expression levels with deficit syndrome severity in chronic schizophrenia patients receiving clozapine treatment. <i>Oncotarget</i> , 2017, 8, 86515-86526.	0.8	4
407	Elevated levels of C-reactive protein and IL-6 among the antipsychotic medicating schizophrenia patients of Siliguri, West Bengal, India. <i>Nordic Journal of Psychiatry</i> , 2018, 72, 311-317.	0.7	7
408	The Paradox of Copy Number Variants in ASD and Schizophrenia: False Facts or False Hypotheses?. <i>Review Journal of Autism and Developmental Disorders</i> , 2018, 5, 199-207.	2.2	3
409	Mechanistic insights into the genetics of affective psychosis from Prader-Willi syndrome. <i>Lancet Psychiatry</i> , 2018, 5, 370-378.	3.7	36
410	Applications of deep learning to MRI images: A survey. <i>Big Data Mining and Analytics</i> , 2018, 1, 1-18.	7.5	195
411	Four-way multimodal fusion of T1-weighted MRI and resting-state fMRI data using an mCCA+jICA model in first-episode schizophrenia. <i>Human Brain Mapping</i> , 2018, 39, 1475-1488.	1.9	24
412	A systematic review of health economic models and utility estimation methods in schizophrenia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 267-275.	0.7	32
413	Can we use mice to study schizophrenia?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2018, 373, 20170032.	1.8	18
414	Assessment of the psychopathological effects of a horticultural therapy program in patients with schizophrenia. <i>Complementary Therapies in Medicine</i> , 2018, 36, 54-58.	1.3	36
415	The multidimensional schizotypy scale-brief: Scale development and psychometric properties. <i>Psychiatry Research</i> , 2018, 261, 7-13.	1.7	34
416	Abdominal Vagal Afferents Modulate the Brain Transcriptome and Behaviors Relevant to Schizophrenia. <i>Journal of Neuroscience</i> , 2018, 38, 1634-1647.	1.7	28
417	Fragment-Based Discovery of Pymido[1,2-b]indazole PDE10A Inhibitors. <i>Chemical and Pharmaceutical Bulletin</i> , 2018, 66, 286-294.	0.6	17
418	Blunted vocal affect and expression is not associated with schizophrenia: A computerized acoustic analysis of speech under ambiguous conditions. <i>Comprehensive Psychiatry</i> , 2018, 83, 84-88.	1.5	6
419	Sleep, circadian rhythms, and schizophrenia. <i>Current Opinion in Psychiatry</i> , 2018, 31, 176-182.	3.1	41
420	Schizophrenia moderates the relationship between white matter integrity and cognition. <i>Schizophrenia Research</i> , 2018, 199, 250-256.	1.1	9
421	Biofeedback to treat anxiety in young people at clinical high risk for developing psychosis. <i>Microbial Biotechnology</i> , 2018, 12, 694-701.	0.9	22
422	Symptom rating scales for schizophrenia and other primary psychotic disorders in ICD-11. <i>Epidemiology and Psychiatric Sciences</i> , 2018, 27, 219-224.	1.8	21
423	Development and psychometric properties of the Multidimensional Schizotypy Scale: A new measure for assessing positive, negative, and disorganized schizotypy. <i>Schizophrenia Research</i> , 2018, 193, 209-217.	1.1	89

#	ARTICLE	IF	CITATIONS
424	A-582941, cholinergic alpha 7 nicotinic receptor agonist, improved cognitive and negative symptoms of the sub-chronic MK-801 model of schizophrenia in rats. <i>Journal of Theoretical Social Psychology</i> , 2018, 28, 4-13.	1.2	4
425	Familial Risk and a Genome-Wide Supported DRD2 Variant for Schizophrenia Predict Lateral Prefrontal-Amygdala Effective Connectivity During Emotion Processing. <i>Schizophrenia Bulletin</i> , 2018, 44, 834-843.	2.3	16
426	DNA methylation and antipsychotic treatment mechanisms in schizophrenia: Progress and future directions. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 38-49.	2.5	67
427	Neurodevelopmental disease mechanisms, primary cilia, and endosomes converge on the BLOC1 and BORG complexes. <i>Developmental Neurobiology</i> , 2018, 78, 311-330.	1.5	21
428	The relationship between psychopathology and cognitive functions with cytokines in clinically stable patients with schizophrenia. <i>Journal of Theoretical Social Psychology</i> , 2018, 28, 66-72.	1.2	11
429	A systematic review of the structural neuroimaging correlates of thought disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 84, 299-315.	2.9	38
430	High C-reactive protein levels are associated with depressive symptoms in schizophrenia. <i>Journal of Affective Disorders</i> , 2018, 225, 671-675.	2.0	30
431	Schizophrenia heterogeneity revisited: Clinical, cognitive, and psychosocial correlates of statistically-derived negative symptoms subgroups. <i>Journal of Psychiatric Research</i> , 2018, 97, 8-15.	1.5	63
432	N-acetyl cysteine reverses bio-behavioural changes induced by prenatal inflammation, adolescent methamphetamine exposure and combined challenges. <i>Psychopharmacology</i> , 2018, 235, 351-368.	1.5	34
433	Attenuated psychotic symptoms in children and adolescent offspring of patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 193, 354-358.	1.1	7
434	A historical account of schizophrenia proneness categories from DSM-I to DSM-5 (1952-2013). <i>Revista Latinoamericana De Psicopatologia Fundamental</i> , 2018, 21, 798-828.	0.0	4
435	Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 55-59.	0.7	27
436	Visuospatial and Sensory Integration Tasks in Patients With Schizophrenia or Schizoaffective Disorder: Relationship to Body Mass Index and Smoking. <i>Frontiers in Psychiatry</i> , 2018, 9, 473.	1.3	2
437	microRNAs Sculpt Neuronal Communication in a Tight Balance That Is Lost in Neurological Disease. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 455.	1.4	47
438	Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018, 9, 622.	1.3	115
439	Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics. <i>Advances in Therapy</i> , 2018, 35, 1994-2014.	1.3	29
440	Omega-3 Fatty Acids and Its Role in Human Health. , 2018, , 173-198.		3
441	Patterns of schizophrenia symptoms: hidden structure in the PANSS questionnaire. <i>Translational Psychiatry</i> , 2018, 8, 237.	2.4	14

#	ARTICLE	IF	CITATIONS
442	Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10017-10039.	2.9	39
443	Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models. <i>Open Biology</i> , 2018, 8, .	1.5	126
444	Value of schizophrenia treatment I: The patient journey. <i>European Psychiatry</i> , 2018, 53, 107-115.	0.1	28
445	Psychotic disorder symptom rating scales: Are dichotomous or multi-point scales more clinically useful? An ICD-11 field study. <i>Schizophrenia Research</i> , 2018, 202, 254-259.	1.1	9
446	A Review of the Effects of Transcranial Direct Current Stimulation for the Treatment of Hallucinations in Patients With Schizophrenia. <i>Journal of ECT</i> , 2018, 34, 164-171.	0.3	19
447	Episodic memory retrieval is impaired in negative schizotypy under fast response deadline. <i>Schizophrenia Research</i> , 2018, 201, 167-171.	1.1	9
448	Trajectories after first episode psychosis: Complement to ambiguous outcomes of long term antipsychotic treatment by exploring a few hidden cases. <i>Microbial Biotechnology</i> , 2019, 13, 895-901.	0.9	5
449	Psychosis in Emerging Adulthood: Phenomenological, Diagnostic, and Clinical Considerations. <i>Evidence-Based Practice in Child and Adolescent Mental Health</i> , 2019, 4, 141-156.	0.7	10
450	Molecular dynamics simulation of biased agonists at the dopamine D2 receptor suggests the mechanism of receptor functional selectivity. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 3206-3225.	2.0	9
451	Basic self-disturbances independently predict recovery in psychotic disorders: A seven year follow-up study. <i>Schizophrenia Research</i> , 2019, 212, 72-78.	1.1	12
452	Nature brings new avenues to the therapy of central nervous system diseases An overview of possible treatments derived from natural products. <i>Science China Life Sciences</i> , 2019, 62, 1332-1367.	2.3	20
453	Synthesis, SAR study, and biological evaluation of novel 2,3-dihydro-1H-imidazo[1,2-a]benzimidazole derivatives as phosphodiesterase 10A inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 3692-3706.	1.4	5
454	The Potential Role of Regulatory Genes (DNMT3A, HDAC5, and HDAC9) in Antipsychotic Treatment Response in South African Schizophrenia Patients. <i>Frontiers in Genetics</i> , 2019, 10, 641.	1.1	3
455	Is there a discrete negative symptom syndrome in people who use methamphetamine?. <i>Comprehensive Psychiatry</i> , 2019, 93, 27-32.	1.5	9
456	The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review. <i>Journal of Clinical Medicine</i> , 2019, 8, 1058.	1.0	57
457	Cognitive Profile in Ultra High Risk for Psychosis and Schizophrenia: A Comparison Using Coordinated Norms. <i>Frontiers in Psychiatry</i> , 2019, 10, 695.	1.3	13
458	Aerobic interval training in standard treatment of outpatients with schizophrenia: a randomized controlled trial. <i>Acta Psychiatrica Scandinavica</i> , 2019, 140, 498-507.	2.2	17
460	Identifying schizophrenia subgroups using clustering and supervised learning. <i>Schizophrenia Research</i> , 2019, 214, 51-59.	1.1	34

#	ARTICLE	IF	CITATIONS
461	Cognitive functioning in patients with first-episode psychosis stratified by level of negative symptoms: A 1-year follow-up study. <i>Psychiatry Research</i> , 2019, 281, 112554.	1.7	10
462	Metabolic profiling identifies TC and LDL as potential serum biomarkers for depressive symptoms in schizophrenia. <i>Psychiatry Research</i> , 2019, 281, 112522.	1.7	18
463	Characterising the structure of cognitive heterogeneity in schizophrenia spectrum disorders. A systematic review and narrative synthesis. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 252-278.	2.9	74
464	Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2019, 10, 605.	1.3	43
465	Dentate Gyrus Immaturity in Schizophrenia. <i>Neuroscientist</i> , 2019, 25, 528-547.	2.6	15
467	Neuroimaging and Psychopathological Domains. , 2019, , 57-155.		3
468	Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia. <i>Health Policy and Technology</i> , 2019, 8, 84-91.	1.3	7
469	Depressive symptoms in schizophrenia patients: A possible relationship between SIRT1 and BDNF. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 95, 109673.	2.5	44
470	Aberrant fronto-striatal connectivity and fine motor function in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2019, 288, 44-50.	0.9	22
471	Social recovery therapy: a treatment manual. <i>Psychosis</i> , 2019, 11, 261-272.	0.4	10
472	Synaptic functions and their disruption in schizophrenia: From clinical evidence to synaptic optogenetics in an animal model. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2019, 95, 179-197.	1.6	50
473	Course and predictors of symptomatic remission in late-life schizophrenia: A 5-year follow-up study in a Dutch psychiatric catchment area. <i>Schizophrenia Research</i> , 2019, 209, 179-184.	1.1	12
474	Cognitive Profiles and Functional Connectivity in First-Episode Schizophrenia Spectrum Disorders â€“ Linking Behavioral and Neuronal Data. <i>Frontiers in Psychology</i> , 2019, 10, 689.	1.1	29
475	Schizophrenia and Progressive Muscle Relaxation â€“ A systematic review of effectiveness. <i>Heliyon</i> , 2019, 5, e01484.	1.4	12
476	Progressive brain structural changes after the first year of treatment in first-episode treatment-naive patients with deficit or nondeficit schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2019, 288, 12-20.	0.9	10
477	Early Somatosensory Processing Over Time in Individuals at Risk to Develop Psychosis. <i>Frontiers in Psychiatry</i> , 2019, 10, 47.	1.3	2
478	Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice. <i>Neuropharmacology</i> , 2019, 150, 1-14.	2.0	29
479	Combining CDP-choline and galantamine, an optimized $\hat{\pm}7$ nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia. <i>International Journal of Psychophysiology</i> , 2019, 145, 70-82.	0.5	17

#	ARTICLE	IF	CITATIONS
480	Association Between Medication Adherence and Oxidative Stress in Patients With First-Episode Mania. <i>Frontiers in Psychiatry</i> , 2019, 10, 162.	1.3	1
481	Morin decreases cortical pyramidal neuron degeneration via inhibition of neuroinflammation in mouse model of schizophrenia. <i>International Immunopharmacology</i> , 2019, 70, 338-353.	1.7	51
482	Development of weCope, a mobile app for illness self-management in schizophrenia. <i>Revista De Psiquiatria Clinica</i> , 2019, 46, 1-4.	0.6	16
483	A Machine Learning Approach for the Automatic Classification of Schizophrenic Discourse. <i>IEEE Access</i> , 2019, 7, 45544-45553.	2.6	7
484	Assessing Outcomes in Schizophrenia in Later Life. , 2019, , 95-111.		0
485	Brain connectivity alterations in early psychosis: from clinical to neuroimaging staging. <i>Translational Psychiatry</i> , 2019, 9, 62.	2.4	31
486	A Systematic Review of the Symptom Profile and Course of Methamphetamine-Associated Psychosis. <i>Substance Use and Misuse</i> , 2019, 54, 549-559.	0.7	48
487	Peer support for people with schizophrenia or other serious mental illness. <i>The Cochrane Library</i> , 2019, 2019, CD010880.	1.5	49
488	Altered levels of dopamine transporter in the frontal pole and dorsal striatum in schizophrenia. <i>NPJ Schizophrenia</i> , 2019, 5, 20.	2.0	24
489	The "Obsessive Paradox". <i>Journal of Nervous and Mental Disease</i> , 2019, 207, 715-720.	0.5	3
490	The Prevalence of Negative Symptoms Across the Stages of the Psychosis Continuum. <i>Harvard Review of Psychiatry</i> , 2019, 27, 15-32.	0.9	22
491	Effects of chronic physical illness on treatment outcomes among patients with schizophrenia. <i>Current Opinion in Psychiatry</i> , 2019, 32, 451-460.	3.1	5
492	The debate about renaming schizophrenia: a new name would not resolve the stigma. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 258-261.	1.8	12
493	Cognitive training improves the disturbed behavioral architecture of schizophrenia-like rats, "Wisket". <i>Physiology and Behavior</i> , 2019, 201, 70-82.	1.0	8
494	Relating constructs of attention and working memory to social withdrawal in Alzheimer's disease and schizophrenia: issues regarding paradigm selection. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 47-69.	2.9	22
495	Schizophrenia and gut-flora related epigenetic factors. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 90, 49-54.	2.5	11
496	Dimensional structure of first episode psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 1431-1438.	0.9	20
497	Variation in fourteen brain structure volumes in schizophrenia: A comprehensive meta-analysis of 246 studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 98, 85-94.	2.9	63

#	ARTICLE	IF	CITATIONS
498	Exploratory Graph Analysis of the Multidimensional Schizotypy Scale. <i>Schizophrenia Research</i> , 2019, 206, 43-51.	1.1	37
499	Sexuality and intimacy among people with serious mental illness: a qualitative systematic review. <i>JBI Database of Systematic Reviews and Implementation Reports</i> , 2019, 17, 74-125.	1.7	32
500	Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimer's disease and schizophrenia: Insights from studies in patient populations and animal models. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 97, 112-137.	2.9	56
501	Post-translational histone modifications and their interaction with sex influence normal brain development and elaboration of neuropsychiatric disorders. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 1968-1981.	1.8	14
502	3D-QSAR studies of D3R antagonists and 5-HT1AR agonists. <i>Journal of Molecular Graphics and Modelling</i> , 2019, 86, 132-141.	1.3	6
503	Clinical correlates of subsyndromal depression in African American individuals with psychosis: The relationship with positive symptoms and comorbid substance dependence. <i>Schizophrenia Research</i> , 2019, 206, 333-346.	1.1	2
504	Prevalence and clinical correlations of obsessive-compulsive symptoms in schizophrenia. <i>Asian Journal of Psychiatry</i> , 2019, 39, 48-52.	0.9	16
505	Blood cell count in antipsychotic-naïve patients with non-effective psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 95-100.	0.9	28
506	Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure. <i>Schizophrenia Bulletin</i> , 2019, 45, 69-79.	2.3	47
507	Preventing discrimination based on psychiatric risk biomarkers. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2019, 180, 159-171.	1.1	10
508	Feasibility and acceptability of brief cognitive remediation targeting metacognition in acute inpatients with psychosis: a case series. <i>Neuropsychological Rehabilitation</i> , 2019, 29, 361-375.	1.0	9
509	Functional connectome organization predicts conversion to psychosis in clinical high-risk youth from the SHARP program. <i>Molecular Psychiatry</i> , 2020, 25, 2431-2440.	4.1	49
510	Brain insulin action in schizophrenia: Something borrowed and something new. <i>Neuropharmacology</i> , 2020, 163, 107633.	2.0	31
511	Design of novel dopamine D2 and serotonin 5-HT2A receptors dual antagonists toward schizophrenia: An integrated study with QSAR, molecular docking, virtual screening and molecular dynamics simulations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 38, 860-885.	2.0	23
512	Transcranial Magnetic Stimulation for Positive Symptoms in Schizophrenia: A Systematic Review. <i>Neuropsychobiology</i> , 2020, 79, 384-396.	0.9	40
513	Cognition and Reward Circuits in Schizophrenia: Synergistic, Not Separate. <i>Biological Psychiatry</i> , 2020, 87, 204-214.	0.7	53
514	What Is Psychosis?. , 2020, , 3-36.		0
515	Effect of aerobic exercise combined with cognitive remediation on cortical thickness and prediction of social adaptation in patients with schizophrenia. <i>Schizophrenia Research</i> , 2020, 216, 397-407.	1.1	21

#	ARTICLE	IF	CITATIONS
516	Cerebral glutamate and GABA levels in high-risk of psychosis states: A focused review and meta-analysis of 1H-MRS studies. <i>Schizophrenia Research</i> , 2020, 215, 38-48.	1.1	36
517	Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate. <i>Drugs - Real World Outcomes</i> , 2020, 7, 19-29.	0.7	174
518	The experience of psychosis and recovery from consumers' perspectives: An integrative literature review. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2022, 29, 99-115.	1.2	8
519	Evidence for altered energy metabolism, increased lactate, and decreased pH in schizophrenia brain: A focused review and meta-analysis of human postmortem and magnetic resonance spectroscopy studies. <i>Schizophrenia Research</i> , 2020, 223, 29-42.	1.1	33
520	Development and Validation of UPLC-MS/MS Method for the Determination of Aripiprazole in Rat Plasma Using Liquid-Liquid Extraction: Pharmacokinetic and Bioequivalence Application. <i>Asian Journal of Chemistry</i> , 2020, 32, 2671-2676.	0.1	0
521	The effect of a plant cultivating program conducted at a community mental health center on the functional remission of individuals with schizophrenia: A randomized controlled study. <i>Archives of Psychiatric Nursing</i> , 2020, 34, 459-466.	0.7	2
522	Automated design and optimization of multitarget schizophrenia drug candidates by deep learning. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112572.	2.6	25
523	Current challenges and possible future developments in personalized psychiatry with an emphasis on psychotic disorders. <i>Heliyon</i> , 2020, 6, e03990.	1.4	15
524	Molecular and biological functions of resveratrol in psychiatric disorders: a review of recent evidence. <i>Cell and Bioscience</i> , 2020, 10, 128.	2.1	23
525	Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders. <i>Molecules</i> , 2020, 25, 5388.	1.7	15
526	Key role for lipids in cognitive symptoms of schizophrenia. <i>Translational Psychiatry</i> , 2020, 10, 399.	2.4	5
527	Neutrophil-to-Lymphocyte Ratio Is Independently Associated With Severe Psychopathology in Schizophrenia and Is Changed by Antipsychotic Administration: A Large-Scale Cross-Sectional Retrospective Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 581061.	1.3	24
528	Polygenic Risk Scores for Subtyping of Schizophrenia. <i>Schizophrenia Research and Treatment</i> , 2020, 2020, 1-13.	0.7	5
529	A brief questionnaire measure of multidimensional schizotypy predicts interview-rated symptoms and impairment. <i>PLoS ONE</i> , 2020, 15, e0237614.	1.1	7
530	Sensitivity and specificity of a facial emotion recognition test in classifying patients with schizophrenia. <i>Journal of Affective Disorders</i> , 2020, 275, 224-229.	2.0	9
531	Schizophrenia in ICD-11: Comparison of ICD-10 and DSM-5. <i>Revista De Psiquiatria Y Salud Mental (English)</i> Tj ETQq1.1 0.784314 rgB / 0.2 6	0.2	6
532	Cognitive Impairment and Diminished Neural Responses Constitute a Biomarker Signature of Negative Symptoms in Psychosis. <i>Schizophrenia Bulletin</i> , 2020, 46, 1269-1281.	2.3	12
533	A Hypothesis Testing for Large Weighted Networks With Applications to Functional Neuroimaging Data. <i>IEEE Access</i> , 2020, 8, 191815-191825.	2.6	1

#	ARTICLE	IF	CITATIONS
534	Design, Synthesis and Biological Investigation of Flavone Derivatives as Potential Multi-Receptor Atypical Antipsychotics. <i>Molecules</i> , 2020, 25, 4107.	1.7	2
535	PSYKOSE: A Motor Activity Database of Patients with Schizophrenia. , 2020, , .		14
536	CDP-choline and galantamine, a personalized ± 7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study. <i>Psychopharmacology</i> , 2020, 237, 3665-3687.	1.5	7
537	<p>Serum C-Reactive Protein in Patients with Deficit Schizophrenia and the Relationship with Cognitive Function</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 2891-2897.	1.0	10
538	Controlled sleep deprivation as an experimental medicine model of schizophrenia: An update. <i>Schizophrenia Research</i> , 2020, 221, 4-11.	1.1	9
539	Altered gamma and theta oscillations during multistable perception in schizophrenia. <i>International Journal of Psychophysiology</i> , 2020, 155, 127-139.	0.5	12
540	Psychosis risk is associated with decreased white matter integrity in limbic network corticostriatal tracts. <i>Psychiatry Research - Neuroimaging</i> , 2020, 301, 111089.	0.9	3
541	Do neurobiological differences exist between paranoid and non-paranoid schizophrenia? Findings from the bipolar schizophrenia network on intermediate phenotypes study. <i>Schizophrenia Research</i> , 2020, 223, 96-104.	1.1	2
542	Neurocognitive and neurophysiological endophenotypes in schizophrenia: An overview. <i>Biomarkers in Neuropsychiatry</i> , 2020, 3, 100017.	0.7	14
543	Different response patterns in hallucinations and delusions to antipsychotic treatment. <i>Nordic Journal of Psychiatry</i> , 2020, 74, 497-504.	0.7	3
544	Social withdrawal: An initially adaptive behavior that becomes maladaptive when expressed excessively. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 116, 251-267.	2.9	14
545	Affective lability across psychosis spectrum disorders. <i>European Psychiatry</i> , 2020, 63, e53.	0.1	17
546	Restricted access carbon nanotube for microextraction by packed sorbent to determine antipsychotics in plasma samples by high-performance liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 2465-2475.	1.9	11
547	Schizotypy, schizotypal personality, and psychosis risk. , 2020, , 81-99.		3
548	Efficacy of psychological interventions targeting cognitive biases in schizophrenia: A systematic review and meta-analysis. <i>Clinical Psychology Review</i> , 2020, 78, 101854.	6.0	38
550	Glutamatergic Contribution to Probabilistic Reasoning and Jumping to Conclusions in Schizophrenia: A Double-Blind, Randomized Experimental Trial. <i>Biological Psychiatry</i> , 2020, 88, 687-697.	0.7	12
551	Cluster A Personality Disorders. , 2020, , 195-211.		2
552	Validation of the Chinese version of the Multidimensional Schizotypy Scale (MSS): Convergent evidence from exploratory and confirmatory factor analyses. <i>Asian Journal of Psychiatry</i> , 2020, 51, 102057.	0.9	7

#	ARTICLE	IF	CITATIONS
553	The gut-microbiome as a target for the treatment of schizophrenia: A systematic review and meta-analysis of randomised controlled trials of add-on strategies. <i>Schizophrenia Research</i> , 2021, 234, 58-70.	1.1	33
554	Positive, Negative, and Disorganized Schizotypy Predict Differential Patterns of Interview-Rated Schizophrenia-Spectrum Symptoms and Impairment. <i>Assessment</i> , 2021, 28, 141-152.	1.9	27
555	Les psychologues dans le champ de la santé mentale: les perspectives en promotion de la santé mentale positive. <i>Pratiques Psychologiques</i> , 2021, 27, 71-84.	0.4	3
556	Anterior vs Posterior Hippocampal Subfields in an Extended Psychosis Phenotype of Multidimensional Schizotypy in a Nonclinical Sample. <i>Schizophrenia Bulletin</i> , 2021, 47, 207-218.	2.3	20
557	Strength training restores force-generating capacity in patients with schizophrenia. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2021, 31, 665-678.	1.3	6
558	Interactions of Antibodies to the Gram-Negative Gastric Bacterium <i>Helicobacter pylori</i> with the Synaptic Calcium Sensor Synaptotagmin 5, Correlate to Impaired Vesicle Recycling in SiMa Human Neuroblastoma Cells. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 481-505.	1.1	2
559	Challenges of Psychiatry Drug Development and the Role of Human Pharmacology Models in Early Development—A Drug Developer's Perspective. <i>Frontiers in Psychiatry</i> , 2020, 11, 562660.	1.3	9
560	Obsessive-Compulsive Schizophrenia and Obsessive-Compulsive Disorder. , 2021, , 33-52.		0
561	Brief Clinical Assessment Scale for Schizophrenia (BCAS-S): development, validity, and reliability study. <i>Noropsikiyatri Arsivi</i> , 2021, 59, 14-20.	0.2	0
562	Divergent relationship between brain structure and cognitive functioning in patients with prominent negative symptomatology. <i>Psychiatry Research - Neuroimaging</i> , 2021, 307, 111233.	0.9	4
563	Evolving Concepts of the Schizophrenia Spectrum: A Research Domain Criteria Perspective. <i>Frontiers in Psychiatry</i> , 2021, 12, 641319.	1.3	17
564	Integrative Analysis Identified Key Schizophrenia Risk Factors from an Abnormal Behavior Mouse Gene Set. <i>Life</i> , 2021, 11, 172.	1.1	2
565	Abnormal semantic processing of threat words associated with excitement and hostility symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2021, 228, 394-402.	1.1	2
566	Mapping relationships among schizophrenia, bipolar and schizoaffective disorders: A deep classification and clustering framework using fMRI time series. <i>Schizophrenia Research</i> , 2022, 245, 141-150.	1.1	25
567	Abnormal regional homogeneity (ReHo) and fractional amplitude of low frequency fluctuations (fALFF) in first-episode drug-naïve schizophrenia patients comorbid with depression. <i>Brain Imaging and Behavior</i> , 2021, 15, 2627-2636.	1.1	21
568	Molecular characterisation of rare loss-of-function NPAS3 and NPAS4 variants identified in individuals with neurodevelopmental disorders. <i>Scientific Reports</i> , 2021, 11, 6602.	1.6	6
569	TPN672: A Novel Serotonin-Dopamine Receptor Modulator for the Treatment of Schizophrenia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 378, 20-30.	1.3	3
570	Targeting muscarinic receptors to treat schizophrenia. <i>Behavioural Brain Research</i> , 2021, 405, 113201.	1.2	37

#	ARTICLE	IF	CITATIONS
571	Prenatal infection and schizophrenia: A decade of further progress. <i>Schizophrenia Research</i> , 2022, 247, 7-15.	1.1	24
572	Relevance of Early Augmentation with Electroconvulsive Therapy in Misidentification Syndrome: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1965-1967.	0.3	0
573	Perceptions of smoking cessation and a novel psychosocial intervention for quitting among individuals with psychosis: A qualitative study. <i>Journal of Community Psychology</i> , 2021, 49, 2738-2752.	1.0	1
574	Chemokine MCP1 is associated with cognitive flexibility in schizophrenia: A preliminary analysis. <i>Journal of Psychiatric Research</i> , 2021, 138, 139-145.	1.5	11
575	Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls. <i>Revista Brasileira De Psiquiatria</i> , 2021, , .	0.9	6
576	The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia. <i>BMC Psychiatry</i> , 2021, 21, 300.	1.1	8
577	Association between empathy and clinical symptoms in chronic schizophrenia: A large sample study based on Chinese Han population. <i>Journal of Psychiatric Research</i> , 2021, 139, 106-112.	1.5	11
578	Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review. <i>Neurology International</i> , 2021, 13, 279-296.	1.3	5
579	Combined Low Dose of Ketamine and Social Isolation: A Possible Model of Induced Chronic Schizophrenia-Like Symptoms in Male Albino Rats. <i>Brain Sciences</i> , 2021, 11, 917.	1.1	4
580	<i>Spirulina platensis</i> reduces the schizophrenic-like symptoms in rat model by restoring altered APO-E and RTN-4 protein expression in prefrontal cortex. <i>Life Sciences</i> , 2021, 277, 119417.	2.0	9
581	Computational models of the "reactive self" and its disturbances in schizophrenia. <i>Consciousness and Cognition</i> , 2021, 93, 103155.	0.8	5
582	Interaction of clozapine with metformin in a schizophrenia rat model. <i>Scientific Reports</i> , 2021, 11, 16862.	1.6	4
583	Schizophrenia: Antipsychotics and drug development. <i>Behavioural Brain Research</i> , 2021, 414, 113507.	1.2	13
584	Mortality and non-use of antipsychotic drugs after acute admission in schizophrenia: A prospective total-cohort study. <i>Schizophrenia Research</i> , 2021, 235, 29-35.	1.1	12
585	A Potential Interface between the Kynurenine Pathway and Autonomic Imbalance in Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10016.	1.8	5
586	Does nicotine exposure during adolescence modify the course of schizophrenia-like symptoms? Behavioral analysis in a phencyclidine-induced mice model. <i>PLoS ONE</i> , 2021, 16, e0257986.	1.1	3
587	The association of multidimensional schizotypy with symptoms and impairment across racial groups. <i>Personality and Mental Health</i> , 2022, 16, 79-89.	0.6	1
588	Taurine prevents MK-801-induced shoal dispersion and altered cortisol responses in zebrafish. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110399.	2.5	8

#	ARTICLE	IF	CITATIONS
589	Social cognition, neurocognition, symptomatology, functional competences and outcomes in people with schizophrenia – A network analysis perspective. <i>Journal of Psychiatric Research</i> , 2021, 144, 8-13.	1.5	17
590	Risk Factors for Deliberate Self-harm and Suicide Among Adolescents and Young Adults With First-Episode Psychosis. <i>Schizophrenia Bulletin</i> , 2022, 48, 414-424.	2.3	10
591	Paranoid Schizophrenia With Voices and Panic Anxiety. , 2021, , 53-65.		0
592	Behavioural Interventions for Weight Management Among Patients with Schizophrenia. , 2017, , 257-273.		1
593	Treatment-Refractory Schizophrenia: Definition and Assessment. , 2014, , 1-19.		7
594	Somatic Problems and Dual Disorder Patients. , 2015, , 349-361.		7
595	Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. , 2017, , 147-191.		2
596	Schizophrenia Spectrum Disorders in Relation to the Totality of Psychosis: From First Episode to Long-Term Outcome. , 2011, , 269-279.		3
598	One Hundred Years of Insanity: Genomic, Psychological, and Evolutionary Models of Autism in Relation to Schizophrenia. , 2011, , 163-185.		8
599	Chronic stress, structural exposures and neurobiological mechanisms: A stimulation, discrepancy and deprivation model of psychosis. <i>International Review of Neurobiology</i> , 2020, 152, 41-69.	0.9	24
600	La esquizofrenia en la CIE-11: comparaci3n con la CIE-10 y el DSM-5. <i>Revista De PsiquiatrAa Y Salud Mental</i> , 2020, 13, 95-104.	1.0	17
602	Hits and false alarms in recognition memory show differential impairment in positive and negative schizotypy.. <i>Journal of Abnormal Psychology</i> , 2019, 128, 633-643.	2.0	14
603	Aberrant Interference of Auditory Negative Words on Attention in Patients with Schizophrenia. <i>PLoS ONE</i> , 2013, 8, e83201.	1.1	9
604	Causas "fracas" e redes causais complexas em psiquiatria. <i>Revista Latinoamericana De Psicopatologia Fundamental</i> , 2014, 17, 15-28.	0.0	1
605	Bir grup ÅYizofreni hastasÄ±nda prodromal evrede risk belirteÅ§lerinin retrospektif deÄYerlendirilmesi. Åžukurova Åœeniversitesi TÄ±p FakÅ¼ltesi Dergisi, 2016, 41, 437-446.	0.0	2
606	Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeksâ€™ Treatment in Patients with Clinically Stable Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 3197-3208.	1.0	5
607	Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review. <i>Current Neuropharmacology</i> , 2014, 12, 273-280.	1.4	68
608	Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders. <i>Current Neuropharmacology</i> , 2017, 15, 800-814.	1.4	28

#	ARTICLE	IF	CITATIONS
609	Epidemiology and Treatment Guidelines of Negative Symptoms in Schizophrenia in Central and Eastern Europe: A Literature Review. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2015, 11, 158-165.	0.6	13
611	Focus on psychosis. <i>Dialogues in Clinical Neuroscience</i> , 2015, 17, 9-18.	1.8	73
612	Schizophrenia and other Psychotic Disorders in DSM-5. <i>Clinical Schizophrenia and Related Psychoses</i> , 2013, 7, 16-19.	1.4	22
613	Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 90.	1.8	21
614	The Concept of Schizophrenia: From the 1850s to the DSM-5. <i>Psychiatric Annals</i> , 2011, 41, 289-295.	0.1	18
615	Brainnetome of schizophrenia: focus on impaired cognitive function. <i>Shanghai Archives of Psychiatry</i> , 2012, 24, 3-10.	0.7	4
616	Cariprazine in Acute Exacerbation of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1574-e1582.	1.1	134
617	Multimodal Hallucinations in Schizophrenia and Its Management. <i>Indian Journal of Psychological Medicine</i> , 2017, 39, 86-88.	0.6	4
618	Psychosis and related disorders in international classification of Disease-11 and their relationship to diagnostic and statistical Manual-5 and international classification of Disease-10. <i>Indian Journal of Social Psychiatry</i> , 2018, 34, 11.	0.3	1
619	Doxycycline Ameliorates Schizophrenia-Like Behaviors in Experimental Models in Mice by Targeting Underlying Oxidative Stress. <i>Journal of Behavioral and Brain Science</i> , 2016, 06, 539-562.	0.2	3
620	Study of negatives symptoms in first episode schizophrenia. <i>Open Journal of Psychiatry</i> , 2013, 03, 323-328.	0.2	1
621	Resilience Improves Neurocognition and Treatment Outcomes in Schizophrenia: A Hypothesis. <i>Open Journal of Psychiatry</i> , 2016, 06, 173-187.	0.2	5
622	A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2012, 10, 61-70.	0.9	65
623	MicroRNAs in the Onset of Schizophrenia. <i>Cells</i> , 2021, 10, 2679.	1.8	23
624	Characterising Demographic, Clinical and Functional Features of Cognitive Subgroups in Schizophrenia Spectrum Disorders: A Systematic Review. <i>Neuropsychology Review</i> , 2022, 32, 807-827.	2.5	8
625	The dual hit hypothesis of schizophrenia: Evidence from animal models. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 131, 1150-1168.	2.9	36
626	Are we ready for a name change for schizophrenia? A survey of multiple stakeholders. <i>Schizophrenia Research</i> , 2021, 238, 152-160.	1.1	23
628	Mutant and Transgenic Tools in Modeling Schizophrenia. <i>Neuromethods</i> , 2010, , 217-239.	0.2	0

#	ARTICLE	IF	CITATIONS
629	Causes. , 2010, , 11-20.		0
630	Glutamatergic Neurotransmission Abnormalities and Schizophrenia. , 2011, , 287-304.		0
631	Genetik bei psychischen Erkrankungen. , 2011, , 127-165.		0
634	The Evolving Nosology of Schizophrenia: Relevance for Treatment. , 2014, , 13-23.		2
635	Overview of Neurobiology. , 2014, , 27-33.		0
637	Autism and Schizophrenia: Genetic and Phenotypic Relationships. , 2014, , 1645-1662.		4
638	Early Antipsychotic Response Predictors in Schizophrenia: A Naturalistic Study. Journal of Psychology & Clinical Psychiatry, 2014, 1, .	0.0	0
639	CHAPTER 3. Developmental Neuroimmune Mechanisms in Schizophrenia. RSC Drug Discovery Series, 2015, , 46-69.	0.2	0
640	Negative symptoms of schizophrenia: A historical, contemporary, and futuristic view. Archives of Medicine and Health Sciences, 2015, 3, 329.	0.0	0
641	Long-Term Clinical Outcome of Patients Using Risperidone Long-Acting Injectable: The Romanian e-STAR Database. Open Journal of Psychiatry, 2015, 05, 153-164.	0.2	1
642	Psychische Störungen. , 2016, , 51-81.		0
644	Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. , 2016, , 1-45.		0
645	Bewegung und psychische Gesundheit. , 2017, , 319-340.		1
646	Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. , 2017, , 1-45.		0
648	Group Horticulture Program on Psychiatric Symptoms in Patients with Chronic Schizophrenia. Journal of Research Development in Nursing and Midwifery, 2017, 14, 16-21.	0.0	1
649	Les différents États psychotiques. , 2018, , 447-503.		0
651	Childhood Affective Indicators of Risk for Adulthood Psychopathology: The New York High-Risk Project Findings. Journal of Psychiatry and Brain Science, 2018, 3, .	0.3	0
652	Progressive muscle relaxation training: classic technique and virtual reality for psychotic patients. Minerva Psichiatrica: A Journal on Psychiatry, Psychology and Psychopharmacology, 2018, 59, .	0.6	4

#	ARTICLE	IF	CITATIONS
654	Brain Structural Changes in Schizophrenia Patients Compared to the Control: An MRI-based Cavalieri's Method. <i>Basic and Clinical Neuroscience</i> , 2023, 14, 355-364.	0.3	2
655	Attenuated Psychosis Syndrome. , 2020, , 159-176.		0
657	...		
658	G Protein-Coupled Estrogen Receptor 1 (GPER) as a Novel Target for Schizophrenia Drug Treatment. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	5
659	Maternal Immune Activation and Neuropsychiatric Disorders: The Intricate Puzzle of Autism Spectrum Disorder. <i>Agents and Actions Supplements</i> , 2020, , 167-205.	0.2	1
661	Regulación Emocional y Funcionamiento Social en Pacientes con Esquizofrenia. <i>Interamerican Journal of Psychology</i> , 2020, 54, e1241.	0.1	1
662	Characteristics of Early Maladaptive Schemas in Individuals with Schizophrenia: A Comparative Study Relative to Major Depressive Disorder. <i>Korean Journal of Schizophrenia Research</i> , 2020, 23, 29-37.	0.3	1
663	A Study of Metabolic Syndrome in Patients on Risperidone. <i>Current Psychopharmacology</i> , 2020, 9, 218-227.	0.1	0
664	14-3-3 proteins in neurological disorders. <i>International Journal of Biochemistry and Molecular Biology</i> , 2012, 3, 152-64.	0.1	88
665	Resource utilization and cost in a commercially insured population with schizophrenia. <i>American Health and Drug Benefits</i> , 2014, 7, 18-26.	0.5	28
666	Research progress in China on the assessment of cognitive function in schizophrenia. <i>Shanghai Archives of Psychiatry</i> , 2013, 25, 266-75.	0.7	2
667	What does schizophrenia teach us about antipsychotics?. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S14-8.	0.9	5
668	Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. <i>Psychopharmacology Bulletin</i> , 2011, 44, 18-31.	0.0	34
669	Clozapine Treatment and Cannabis Use in Adolescents with Psychotic Disorders - A Retrospective Cohort Chart Review. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2017, 26, 51-58.	0.7	5
670	Study protocol for a prospective cohort study examining the predictive potential of dynamic symptom networks for the onset and progression of psychosis: the Mapping Individual Routes of Risk and Resilience (Mirorr) study. <i>BMJ Open</i> , 2018, 8, e019059.	0.8	6
671	Changes in social functioning over the course of psychotic disorders – A meta-analysis. <i>Schizophrenia Research</i> , 2022, 239, 55-82.	1.1	19
672	Evidence for the Association between the Intronic Haplotypes of Ionotropic Glutamate Receptors and First-Episode Schizophrenia. <i>Journal of Personalized Medicine</i> , 2021, 11, 1250.	1.1	1
673	A change in taste: the role of microRNAs in altering hedonic value. <i>Journal of Experimental Biology</i> , 2022, 225, .	0.8	6

#	ARTICLE	IF	CITATIONS
674	Network Analysis-Based Disentanglement of the Symptom Heterogeneity in Asian Patients with Schizophrenia: Findings from the Research on Asian Psychotropic Prescription Patterns for Antipsychotics. <i>Journal of Personalized Medicine</i> , 2022, 12, 33.	1.1	4
675	The relationship between clinical recovery and personal recovery among people living with schizophrenia: A serial mediation model and the role of disability and quality of life. <i>Schizophrenia Research</i> , 2022, 239, 168-175.	1.1	11
676	Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia. <i>Journal of Psychopharmacology</i> , 2022, 36, 183-190.	2.0	6
677	Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 37-42.	0.7	8
678	Hippocampal Subfield Volumes and Cognitive Function in Schizophrenia and Mood Disorders. <i>Neuropsychobiology</i> , 2022, 81, 204-214.	0.9	6
679	The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study. <i>Biomedicines</i> , 2022, 10, 243.	1.4	7
680	Association between C-reactive protein levels and antipsychotic treatment during 12-months follow-up period after acute psychosis. <i>Schizophrenia Research</i> , 2022, 241, 174-183.	1.1	3
681	Study protocol for a prospective cohort study examining the predictive potential of dynamic symptom networks for the onset and progression of psychosis: the Mapping Individual Routes of Risk and Resilience (Mirorr) study. <i>BMJ Open</i> , 2018, 8, e019059.	0.8	16
683	The association between clinical symptoms and later subjective quality of life in individuals with ultra-high risk for psychosis and recent-onset psychotic disorder: A longitudinal investigation. <i>Psychiatry and Clinical Neurosciences</i> , 2022, , .	1.0	3
684	Models of Care of Schizophrenia in the Community—An International Perspective. <i>Current Psychiatry Reports</i> , 2022, 24, 195-202.	2.1	7
685	RNA-seq analysis of gene expression profiles in posttraumatic stress disorder, Parkinson's disease and schizophrenia identifies roles for common and distinct biological pathways. <i>Discover Mental Health</i> , 2022, 2, .	1.0	4
686	Motor abnormalities are associated with poor social and functional outcomes in schizophrenia. <i>Comprehensive Psychiatry</i> , 2022, 115, 152307.	1.5	17
687	Mismatch Negativity and P3a Impairment through Different Phases of Schizophrenia and Their Association with Real-Life Functioning. <i>Journal of Clinical Medicine</i> , 2021, 10, 5838.	1.0	8
688	Improving Knowledge on Pathways to Functional Outcome in Schizophrenia: Main Results From the Italian Network for Research on Psychoses. <i>Frontiers in Psychiatry</i> , 2021, 12, 791117.	1.3	15
689	“Gypsum on water. That schizophrenia.” schizophrenia “a meeting of stories: a qualitative study. <i>Disability and Society</i> , 2024, 39, 145-173.	1.4	0
690	Diagnostic classification of schizophrenia and bipolar disorder by using dynamic functional connectivity: An fNIRS study. <i>Journal of Neuroscience Methods</i> , 2022, 376, 109596.	1.3	6
691	Association of VEGF-A and KDR polymorphisms with the development of schizophrenia. <i>Human Immunology</i> , 2022, 83, 528-537.	1.2	6
700	Processing environmental stimuli in paranoid schizophrenia: recognizing facial emotions and performing executive functions. <i>Biomedical and Environmental Sciences</i> , 2012, 25, 697-705.	0.2	4

#	ARTICLE	IF	CITATIONS
703	Identification of Schizophrenic Individuals Using Activity Records Through Visualization of Recurrent Networks. Lecture Notes in Networks and Systems, 2022, , 653-664.	0.5	6
704	Emerging Roles of FTO in Neuropsychiatric Disorders. BioMed Research International, 2022, 2022, 1-9.	0.9	8
705	Styles of Coping with Stress among Healthy People and People with Diagnosis of Schizophrenia and Selected Personality Dimensions. International Journal of Environmental Research and Public Health, 2022, 19, 5129.	1.2	0
706	Development of a Mobile Assessment Tool for Understanding Social Comparison Processes Among Individuals With Schizophrenia: Two-Phase Survey Study. JMIR Formative Research, 2022, 6, e36541.	0.7	3
707	Ð¹½Ñ, Ð¾¼ÑÐ¹¼Ð°Ñ†Ð, Ð¾¾Ð¹½Ð¹½Ð°Ñ¹¼Ð¾¾Ð¹µÐ»ÑÐ¹¼Ñ¹Ð»Ð¹µÐ¹½Ð,Ñ¹Ð».Ðœ.Ð¹µÐ¹Ð¹µÑ¹Ð° Ð² Ð,ÑÑÐ»ÐµÐ¹Ð¾Ð²Ð²		
711	Schizophrenia Spectrum and Other Psychotic Disorders. , 2022, , .		0
712	Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium. BMC Psychiatry, 2022, 22, .	1.1	2
713	Antipsychotic Drug Development: From Historical Evidence to Fresh Perspectives. Frontiers in Psychiatry, 0, 13, .	1.3	7
714	Brain Stimulation and Group Therapy to Improve Gesture and Social Skills in Schizophreniaâ€”The Study Protocol of a Randomized, Sham-Controlled, Three-Arm, Double-Blind Trial. Frontiers in Psychiatry, 0, 13, .	1.3	1
715	Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats. Inflammopharmacology, 2022, 30, 1891-1907.	1.9	10
716	Increased brain gyrification and subsequent relapse in patients with first-episode schizophrenia. Frontiers in Psychiatry, 0, 13, .	1.3	2
717	Clinical and psychosocial outcomes of Black Americans in the Recovery After an Initial Schizophrenia Episode Early Treatment Program (RAISE-ETP) study. Social Psychiatry and Psychiatric Epidemiology, 0, , .	1.6	5
718	Schizophrenia and psychedelic state: Dysconnection versus hyper-connection. A perspective on two different models of psychosis stemming from dysfunctional integration processes. Molecular Psychiatry, 2023, 28, 59-67.	4.1	6
719	Efficacy of nutrition education for the increase of symbiotic intake on nutritional and metabolic status in schizophrenic spectrum disorders: A two-arm protocol. Frontiers in Nutrition, 0, 9, .	1.6	1
720	The clinical and psychosocial correlates of self-stigma among people with schizophrenia spectrum disorders across cultures: A systematic review and meta-analysis. Schizophrenia Research, 2022, 248, 64-78.	1.1	8
721	Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting Haloperidol Exposure in Healthy and Disease Populations. Pharmaceutics, 2022, 14, 1795.	2.0	2
722	Cognitive Enhancement Therapy vs social skills training in schizophrenia: a cluster randomized comparative effectiveness evaluation. BMC Psychiatry, 2022, 22, .	1.1	3
723	Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials. Schizophrenia Bulletin, 2023, 49, 11-23.	2.3	10

#	ARTICLE	IF	CITATIONS
724	Bio-behavioural changes in treatment-resistant socially isolated FSL rats show variable or improved response to combined fluoxetine-olanzapine versus olanzapine treatment. <i>IBRO Neuroscience Reports</i> , 2022, 13, 284-298.	0.7	4
725	Clinical and psychological factors associated with resilience in patients with schizophrenia: data from the Italian network for research on psychoses using machine learning. <i>Psychological Medicine</i> , 0, , 1-12.	2.7	1
726	Schizophrenia: One Name, Many Different Manifestations. <i>Medical Clinics of North America</i> , 2023, 107, 61-72.	1.1	12
727	Mismatch negativity and clinical trajectories in psychotic disorders: Five-year stability and predictive utility. <i>Psychological Medicine</i> , 2023, 53, 5818-5828.	2.7	4
728	Randomized Controlled Trials of Digital Mental Health Interventions on Patients with Schizophrenia Spectrum Disorder: A Systematic Review. <i>Telemedicine Journal and E-Health</i> , 0, , .	1.6	0
729	Inefficient white matter activity in Schizophrenia evoked during intra and inter-hemispheric communication. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	2
730	Psychotic relapse in people with schizophrenia within 12 months of discharge from acute inpatient care: protocol for development and validation of a prediction model based on a retrospective cohort study in three psychiatric hospitals in Japan. <i>Diagnostic and Prognostic Research</i> , 2022, 6, .	0.8	1
731	A narrative review of treatment interventions to improve cognitive performance in schizophrenia, with an emphasis on at-risk and early course stages. <i>Psychiatry Research</i> , 2022, 317, 114926.	1.7	1
732	Adolescent nicotine potentiates the inhibitory effect of raclopride, a D2R antagonist, on phencyclidine-sensitized psychotic-like behavior in mice. <i>Toxicology and Applied Pharmacology</i> , 2022, 456, 116282.	1.3	1
733	NOWE KIERUNKI POSZUKIWAÅf LEKÅ“W ANTYPHYCHOTYCZNYCH. , 2014, 13, 21-27.		0
734	Classification of Schizophrenia and Alzheimer's Disease using Resting-State Functional Network Connectivity. , 2022, , .		2
735	Substance use and psychotic-like experiences in young people: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 0, , 1-15.	2.7	5
736	Social anhedonia and other indicators of risk for schizophrenia: Theory and inquiry. <i>Psychiatry Research</i> , 2023, 319, 114966.	1.7	1
737	Social anhedonia in Malaysian schizophrenia patients and healthy participants. <i>Asian Journal of Psychiatry</i> , 2023, 79, 103350.	0.9	2
738	Current Status of Therapeutic Drug Monitoring in Mental Health Treatment: A Review. <i>Pharmaceutics</i> , 2022, 14, 2674.	2.0	10
739	Adolescent raloxifene treatment in females prevents cognitive deficits in a neurodevelopmental rodent model of schizophrenia. <i>Behavioural Brain Research</i> , 2022, , 114276.	1.2	3
740	Relationship between dairy product intake and sense of coherence among middle and high school students in Japan. <i>PLoS ONE</i> , 2022, 17, e0279232.	1.1	0
741	Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 0, , .	1.8	2

#	ARTICLE	IF	CITATIONS
742	A Diagnostic Perspective of Schizophrenia: From Past to Present. , 2023, , 45-70.		0
743	Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. Life Sciences, 2023, , 121366.	2.0	3
744	Rehabilitation of Schizophrenia: Practical Interventions. , 2023, , 229-248.		0
745	Different Phases of Schizophrenia Patients: From the Psychological Perspective. , 2023, , 197-213.		0
746	Schizophrenia among young people first admitted to psychiatric inpatient care during early and middle adolescence. Schizophrenia Research, 2023, 252, 103-109.	1.1	0
747	Psychomotor slowing alters gait velocity, cadence, and stride length and indicates negative symptom severity in psychosis. , 2022, 8, .		3
748	The Role of microRNA in the Pathogenesis of Schizophrenia. The Neuroscience Journal of Shefaye Khatam, 2022, 11, 119-132.	0.4	0
749	Modulation of circuit oscillations in the rat anterior cingulate cortex (ACC) in vitro by mGlu2 metabotropic glutamate receptors and alleviation of the effects of phencyclidine-induced NMDA-receptor hypofunction. Pharmacology Biochemistry and Behavior, 2023, 223, 173532.	1.3	1
750	Vortioxetine improved negative and cognitive symptoms of schizophrenia in subchronic MK-801 model in rats. Behavioural Brain Research, 2023, 444, 114365.	1.2	6
752	Sex-specific susceptibility to psychotic-like states provoked by prenatal <sc>THC</sc> exposure: Reversal by pregnenolone. Journal of Neuroendocrinology, 2023, 35, .	1.2	4
753	Reinventing schizophrenia: Updating the construct. Project update and next steps. Schizophrenia Research, 2023, 252, 345-347.	1.1	2
754	Investigation of social and cognitive predictors in non-transition ultra-high-risk™ individuals for psychosis using spiking neural networks. , 2023, 9, .		3
755	Microglia and microbiome in schizophrenia: can immunomodulation improve symptoms?. Journal of Neural Transmission, 0, , .	1.4	1
756	Factors Contributing to Risk of Persistence of Positive and Negative Symptoms in Schizophrenia during Hospitalization. International Journal of Environmental Research and Public Health, 2023, 20, 4592.	1.2	1
757	Development and validation of predictive model for a diagnosis of first episode psychosis using the multinational EU-GEI case-control study and modern statistical learning methods. Schizophrenia Bulletin Open, 0, , .	0.9	0
759	Perspectivas sobre a Esquizofrenia: da medicina psiquiátrica À terapia psicanalítica. Archives of Health, 2023, 4, 208-227.	0.0	0
760	Interhemispheric differences of pyramidal cells in the primary motor cortices of schizophrenia patients investigated postmortem. Cerebral Cortex, 2023, 33, 8179-8193.	1.6	1
761	Antiviral treatment in schizophrenia: a randomized pilot PET study on the effects of valaciclovir on neuroinflammation. Psychological Medicine, 2023, 53, 7087-7095.	2.7	2

#	ARTICLE	IF	CITATIONS
772	Schizophrenia in the genetic era: a review from development history, clinical features and genomic research approaches to insights of susceptibility genes. <i>Metabolic Brain Disease</i> , 0, , .	1.4	0
781	Conceptualization and Assessment of Multidimensional Schizotypy. , 2023, , 81-95.		0
782	Schizophrenia or Other Primary Psychotic Disorders. , 2023, , 25-38.		0
797	Psychische Störungen. , 2023, , 59-95.		0